Rank	Title	Status	Study Results	Conditions	Interventions	Locations	URL
1	Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas	Recruiting	No Results Available	T Cell Lymphoma	Drug: Brentuximab Vedotin	The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States	https://ClinicalTrials.gov/show/NCT04334174
2	Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma	Not yet recruiting	No Results Available	Peripheral T-cell Lymphoma	Drug: Decitabine|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone		https://ClinicalTrials.gov/show/NCT03553537
3	Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	Recruiting	No Results Available	Peripheral T-cell Lymphoma	Drug: CHOP for 6 cycles|Drug: CHOP+X for 6 cycles	Shanghai Ruijin Hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT04480099
4	A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma	Recruiting	No Results Available	Cutaneous T Cell Lymphoma|Peripheral T Cell Lymphoma	Device: Microdevices|Other: Standard of care therapy|Other: Standard of care systemic therapy	Dana Farber Cancer Institute, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT04045470
5	Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma	Not yet recruiting	No Results Available	NK/T Cell Lymphoma	Drug: Dexamethasone, azacytidine, Pegaspargase, Tislelizumab	National Cancer Center/Cancer Hosptial, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China|Peking University International Hospital, Beijing, Beijing, China|Peking University Cancer Hospital & Institute, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04899414
6	CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma	Recruiting	No Results Available	Peripheral T Cell Lymphoma	Biological: ATLCAR.CD30 T cells|Drug: Bendamustine|Drug: Fludarabine|Drug: Cyclophosphamide	Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States	https://ClinicalTrials.gov/show/NCT04083495
7	Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study	Recruiting	No Results Available	Cutaneous T-cell Lymphoma	Drug: Sintilimab|Drug: Chidamide	Peking Union Medical College Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04296786
8	Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma	Recruiting	No Results Available	T Cell Non-Hodgkin's Lymphoma	Drug: Chidamide|Drug: Cyclophosphamide|Drug: Epirubicin|Drug: Vindesine|Drug: Etoposide|Drug: Prednisone	Peking Union medical college hospital, Beijing, Beijing, China|Tianjin medical universty cancer institute & hospital, Tianjin, Tianjin, China	https://ClinicalTrials.gov/show/NCT02987244
9	Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study	Recruiting	No Results Available	Peripheral T-cell Lymphoma	Drug: BEAC|Drug: Cladribine combined with BEAC	Ruijin Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04880746
10	A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma	Recruiting	No Results Available	T-cell Lymphoma	Drug: CPI-818	Stanford University, Palo Alto, California, United States|University of Michigan, Ann Arbor, Michigan, United States|Washington University, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Ohio State University, Columbus, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Epworth Healthcare, Melbourne, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Linear Clinical Research, Perth, Western Australia, Australia|Seoul National University Hospital, Seoul, Gyeonggido, Korea, Republic of|Asan Medical Center, Seoul, Gyeonggido, Korea, Republic of|Samsung Medical Center, Seoul, Gyeonggido, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Gyeonggido, Korea, Republic of|Inje University Busan-Paik Hospital, Busan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Gachon University, Incheon, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03952078
11	Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)	Recruiting	No Results Available	Cutaneous T Cell Lymphoma	Drug: Micro needle array-Doxorubicin (MNA-D)	University Of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT02192021
12	PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma	Recruiting	No Results Available	NK/T Cell Lymphoma	Drug: PD-1 Antibody, chidamide, lenalidomide and etoposide	Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China	https://ClinicalTrials.gov/show/NCT04038411
13	Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma	Recruiting	No Results Available	Peripheral T-cell Lymphoma	Drug: PD-1 antibody+ HDAC inhibitor	Dongmei Ji, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04512534
14	PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma	Recruiting	No Results Available	Peripheral T-cell Lymphoma	Drug: PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine	Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China	https://ClinicalTrials.gov/show/NCT04040491
15	Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type	Recruiting	No Results Available	NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis)|NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)	Drug: Pembrolizumab	Stanford University, Stanford, California, United States|Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Hackensack Meridian Health, Hackensack, New Jersey, United States|Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memoral Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|Md Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT03728972
16	Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma	Recruiting	No Results Available	T-cell Lymphoma|Relapsed and Refractory T-cell Lymphoma	Drug: Ibrutinib	Memorial Sloan Kettering Cancer Center, New York, New York, United States|Ohio State University, Columbus, Ohio, United States	https://ClinicalTrials.gov/show/NCT02309580
17	A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma	Recruiting	No Results Available	NK/T-Cell Lymphoma	Drug: Chidamide+ Etoposide	Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China	https://ClinicalTrials.gov/show/NCT04490590
18	A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）	Not yet recruiting	No Results Available	Peripheral T-cell Lymphoma	Drug: TQ-B3525	Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China|Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04615468
19	A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma	Recruiting	No Results Available	Persistent or Recurrent Cutaneous T-Cell Lymphoma	Drug: E7777 9 mcg/kg	University of Alabama at Birmingham, Dermatology at Whitaker Clinic, Birmingham, Alabama, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|City of Hope Medical Center National Medical Center, Duarte, California, United States|UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange, California, United States|Stanford University Cancer Center, Stanford, California, United States|Yale University Cancer Center, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|University of South Florida College of Medicine, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center, New York, New York, United States|University of PittsburghMedical Center Presbyterian Shadyside, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|The University of TX MD Anderson Cancer Center, Houston, Texas, United States|Westmead Hospital, Westmead, New South Wales, Australia|Epworth Healthcare Freemasons, East Melbourne, Victoria, Australia|Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia|Auxilio Mutuo Cancer Center, San Juan, Puerto Rico	https://ClinicalTrials.gov/show/NCT01871727
20	Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma	Recruiting	No Results Available	Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type	Drug: LEAP regimen	Xinhua Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04004572
21	A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma	Recruiting	No Results Available	Peripheral T Cell Lymphoma	Drug: Bortezomib|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Pharmorubicin|Drug: Prednisone	Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04061772
22	A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma	Not yet recruiting	No Results Available	Peripheral T Cell Lymphoma	Drug: SHC014748M treatment		https://ClinicalTrials.gov/show/NCT04470141
23	Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma	Not yet recruiting	No Results Available	Stage IB-IIB Cutaneous T-Cell Lymphoma	Drug: Mogamulizumab|Radiation: Total Skin Electron Beam Therapy (TSEB)|Drug: Mogamulizumab (subsequent cycles post TSEB)		https://ClinicalTrials.gov/show/NCT04128072
24	A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma	Recruiting	No Results Available	Peripheral T-cell Lymphoma	Biological: AK104	Beijing Cancer Hospital, Beijing, Beiing, China	https://ClinicalTrials.gov/show/NCT04444141
25	The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).	Not yet recruiting	No Results Available	Peripheral T Cell Lymphoma	Drug: F520		https://ClinicalTrials.gov/show/NCT04457830
26	Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas	Recruiting	No Results Available	Peripheral T Cell Lymphoma	Drug: Nivolumab and EPOCH	City of Hope Cancer Center, Duarte, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT03586999
27	Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma	Recruiting	No Results Available	NK/T Cell Lymphoma Nos	Drug: Sintilimab|Drug: Lenalidomide	Beijing Tongren Hospital, Beijing, China	https://ClinicalTrials.gov/show/NCT04231370
28	Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma	Recruiting	No Results Available	Peripheral T-cell Lymphoma	Drug: Cyclophosphamide|Drug: pegylated liposomal doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Doxorubicin	Peking University Cancer Hospital & Institute, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03952572
29	A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma	Recruiting	No Results Available	Peripheral T-cell Lymphoma|NK/T-cell Lymphoma	Combination Product: ICE [ifosfamide+carboplatin+etoposide]|Combination Product: GEMOX [gemcitabine+oxaliplatin]	Peking University Third Hospital, Beijing, Beijing, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Tianjin Medical Universisity Cancer Institute & Hospital, Tianjin, Tianjin, China|The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04425070
30	LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma	Recruiting	No Results Available	CD4+ T-cell Lymphoma	Drug: Efficacy of LCAR-T2C CAR-T cells	Hematological Department, People's Hospital of Jiangsu Province, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT04219319
31	Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)	Recruiting	No Results Available	Peripheral T Cell Lymphoma	Biological: GB226	Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03502629
32	Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type	Recruiting	No Results Available	NK/T Cell Lymphoma Nos	Drug: sintilimab,pegaspargase,gemcitabine,oxaliplatin	Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04127227
33	A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)	Recruiting	No Results Available	NK/T Cell Lymphoma Nos	Drug: Toripalimab|Drug: Pegaspargase|Drug: Gemcitabine|Drug: Oxaliplatin|Radiation: Definitive intensity-modulated radiotherapy (IMRT)	Guangdong General Hospital, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04365036
34	Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)	Recruiting	No Results Available	Cutaneous T Cell Lymphoma	Drug: dimethylfumarate	University Medical Center, Mannheim, Germany	https://ClinicalTrials.gov/show/NCT02546440
35	Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma	Not yet recruiting	No Results Available	Extranodal NK/T-cell Lymphoma, Nasal Type	Drug: toripalimab		https://ClinicalTrials.gov/show/NCT04338282
36	Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas	Recruiting	No Results Available	Peripheral T-cell Lymphoma	Drug: Fenretinide	Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Emory University, Atlanta, Georgia, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Norton Healthcare, Louisville, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Bon Secours Saint Francis Cancer Center, Greenville, South Carolina, United States|Baylor University Medical Center, Dallas, Texas, United States|University of Texas, Southwestern, Dallas, Texas, United States	https://ClinicalTrials.gov/show/NCT02495415
37	Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas	Recruiting	No Results Available	Peripheral T Cell Lymphoma	Drug: cisplatin|Drug: ifosfamide|Drug: gemcitabine|Drug: L-asparaginase|Drug: etoposide|Drug: dexamethasone	The University of Hong Kong, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT03071822
38	A Multicenter Clinical Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin in Patients With Relapsed/Refractory CD38 Positive PTCL-NOS, Angioimmunoblastic T-cell Lymphoma AITL and Other Nodal Lymphomas of T Follicular Helper Cells Origin	Recruiting	No Results Available	Refractory T-Cell Lymphoma|Relapsed T-Cell Lymphoma	Drug: Daratumumab	Casa Sollievo della Sofferenza - U.O. Ematologia, San Giovanni Rotondo, Foggia, Italy|Azienda Ospedaliera S.Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico, Avellino, Italy|IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia, Bari, Italy|Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele Presidio Ospedale Ferrarotto - Ematologia, Catania, Italy|A.O. S. Croce e Carle - S.C. di Ematologia e Trapianto di Midollo Osseo, Cuneo, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia, Meldola, Italy|IEO Istitito Europeo di Oncologia - Divisione Ematoncologia, Milano, Italy|ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia, Milano, Italy|AOU Federico II - Ematologia, Napoli, Italy|A.O. Ospedali Riuniti Villa Sofia-Cervello - Divisione di Ematologia, Palermo, Italy|Ospedale Guglielmo da Saliceto - U.O.Ematologia, Piacenza, Italy|AOU Pisana - U.O. Ematologia, Pisa, Italy|Ospedale degli Infermi di Rimini - U.O. di Ematologia, Rimini, Italy|Policlinico Tor Vergata - Ematologia, Roma, Italy|Ospedale S. Camillo - Ematologia, Roma, Italy|AOU Senese - U.O.C. Ematologia, Siena, Italy|A.O.U. Citta della Salute e della Scienza di Torino - Ematologia Universitaria, Torino, Italy|Ospedale Ca Foncello - S.C di Ematologia, Treviso, Italy|Trieste - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) - SC Ematologia, Trieste, Italy|AOU Integrata di Verona - U.O. Ematologia, Verona, Italy	https://ClinicalTrials.gov/show/NCT04251065
39	A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)	Recruiting	No Results Available	Extranodal Natural Killer/T-Cell Lymphoma	Biological: CS1001	The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03595657
40	Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma	Recruiting	No Results Available	Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type	Drug: Anlotinib	Xinhua Hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT03618238
41	Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma	Recruiting	No Results Available	Extranodal NK/T-cell Lymphoma	Drug: Sintilimab|Drug: Decitabine	Beijing Tongren Hospital, Beijing, China	https://ClinicalTrials.gov/show/NCT04279379
42	Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma	Recruiting	No Results Available	Relapsed or Refractory Peripheral T-cell Lymphoma	Drug: Chidamide, Lenalidomide	Guangdong General Hospital, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04329130
43	A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma	Recruiting	No Results Available	Relapsed or Refractory Peripheral T-Cell Lymphoma	Drug: YY-20394	Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin, Tianjin, China	https://ClinicalTrials.gov/show/NCT04108325
44	A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma	Recruiting	No Results Available	Cutaneous T-cell Lymphoma (CTCL)	Drug: Romidepsin|Drug: Brentuximab vedotin	Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT02616965
45	Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma	Recruiting	No Results Available	Nasal Type Extranodal NK/T-Cell Lymphoma	Drug: Pegaspargase|Drug: Anti-PD-1 monoclonal antibody	Ruijin hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04096690
46	Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma	Recruiting	No Results Available	Angioimmunoblastic T-cell Lymphoma	Drug: Chidamide|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone	Ruijin hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT03853044
47	Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma	Recruiting	No Results Available	NK/T Cell Lymphoma Nos	Drug: pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone	Peking University Cancer Hospital & Institute, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04484506
48	GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma	Recruiting	No Results Available	Extranodal NK/T-cell Lymphoma	Drug: Gemcitabine|Drug: Pegaspargase|Drug: Etoposide|Drug: Dexamethasone	Beijing Tongren Hospital, Beijing, China	https://ClinicalTrials.gov/show/NCT04917250
49	A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type	Recruiting	No Results Available	Extranodal NK/T-cell Lymphoma, Nasal Type|Extranodal NK/T-cell Lymphoma	Drug: IMC-001	Chonnam National University Hwasun Hospital, Hwasun, Chonnam, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT04414163
50	VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients	Recruiting	No Results Available	Extranodal NK/T-cell Lymphoma	Biological: VT-EBV-N|Other: Placebo	Inje University Busan Paik Hospital, Busan, Korea, Republic of|Keimyung University Daegu Dongsan Hospital, Daegu, Korea, Republic of|Hallym Univ. Medical Center, Gyeonggi-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Seoul St.Mary's Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03671850
51	B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma	Recruiting	No Results Available	Extranodal NK/T-cell Lymphoma	Drug: B-MAD chemotherapy	King Chulalongkorn Memorial Hospital, Bangkok, Thailand	https://ClinicalTrials.gov/show/NCT03246750
52	IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma	Recruiting	No Results Available	Lymphoma, T-Cell|Lymphoma, T-Cell, Cutaneous|Mycosis Fungoides/Sezary Syndrome	Biological: IPH4102	University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California, United States|Stanford Cancer Center, Stanford, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Universal Dermatology, PLLC68, Fairport, New York, United States|Columbia University Pediatric Neuromuscular Center Columbia UMC, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Inova Health Care Services, Fairfax, Virginia, United States|CHU de Bordeaux Saint André, Bordeaux, France|CHU Henri Mondor, Créteil, France|CHRU de Lille - Hopital Claude Huriez, Lille, France|Centre Hospitalier Lyon-Sud, Lyon, France|Institut Paoli-Calmettes, Marseille, France|CHRU de Montpellier - Hopital Saint Eloi, Montpellier, France|Hôpital Saint-Louis Service de Dermatologie, Paris, France|CHU Rennes - Hopital Pontchaillou, Rennes, France|Hôpital Charles Nicolle-CHU de Rouen Clinique Dermatologie, Rouen, France|Institut Claudius Regaud Département de Dermatologie, Toulouse, France|CHRU de Tours, Hôpital Trousseau, service Dermatologie, Tours, France|Dermatology, Ruhr-University Bochum, Bochum, Germany|Universitaetsklinikum Halle (Saale), Halle, Germany|Universitaetsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Johannes Wesling Klinikum Minden, Minden, Germany|Istituto di Ematologia Lorenzo e Ariosto Seragnoli, Bologna, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|Istituto Dermopatico dell'Immacolata (IDI-IRCCS), Roma, Italy|Universita di Torino, Turin, Italy|Hospital Clinic Barcelona, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Consorci Hospital General Universitari de Valencia Servicio de Dermatología, Valencia, Spain|University of Birmingham, Birmingham, United Kingdom|Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom|Cancer Research UK - Christie Hospital Foundation NHS Trust - Dept of Medical Oncology, Manchester, United Kingdom	https://ClinicalTrials.gov/show/NCT03902184
53	VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)	Recruiting	No Results Available	Extranodal NK-T-Cell Lymphoma	Drug: Etoposide|Drug: Ifosfamide|Drug: Dexamethasone|Drug: L-asparaginase|Drug: Busulfan|Drug: Melphalan	Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02544425
54	Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial	Recruiting	No Results Available	Extranodal NK/T Cell Lymphoma, Nasal Type	Drug: IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)	Sun Yat-sen University Cancer Center, Guangdong, China	https://ClinicalTrials.gov/show/NCT04602065
55	Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma	Recruiting	No Results Available	Lymphoma, T-Cell, Cutaneous|Lymphoma, T-Cell, Peripheral|Hodgkin Lymphoma	Drug: Lenalidomide 15mg|Drug: Brentuximab Vedotin 1.8 mg/Kg	Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia	https://ClinicalTrials.gov/show/NCT03302728
56	GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma	Recruiting	No Results Available	Extranodal NK-T-Cell Lymphoma, Nasal Type	Drug: GELAD|Radiation: Radiotherapy	Shanghai Dong Fang hospital, Shanghai, Shanghai, China|Department of Hematology, Renji Hospital, Shanghai, Shanghai, China|South Renji hospital, Shanghai, Shanghai, China|Xin Jiang People's Hospital, Urumqi, Xinjiang, China|Shanghai Ninth Peoples' Hospital, Shanghai, China|Shanghai Eye and ENT Hospital of Fudan University, Shanghai, China|Xinhua Hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT02733458
57	Clinical Trial to Evaluate the Efficacy and Safety of Epstein-Barr Virus Induced Natural T Lymphocyte(EBViNT) Cell in Patients With Progressive EBV Positive Extranodal NK/T-cell Lymphoma Where Standard Treatments Have Failed	Recruiting	No Results Available	EBV Associated Extranodal NK/T-cell Lymphoma	Biological: EBViNT Cell	Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03789617
58	Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type	Recruiting	No Results Available	Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type	Other: chemotherapy followed by radiotherapy|Other: radiotherapy followed by chemotherapy|Drug: IPGDP regimen chemotherapy	Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China|People's Hospital of Guangxi, Nanning, China|Fourth Hospital of Hebei Medical University, Shijiazhuang, China|Shanxi Dayi Hospital, Taiyuan, China|Shanxi Province Cancer Hospital, Taiyuan, China	https://ClinicalTrials.gov/show/NCT02560441
59	REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)	Not yet recruiting	No Results Available	Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL) (Stage IA-IB)	Drug: chlormethine gel		https://ClinicalTrials.gov/show/NCT04218825
60	Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas	Recruiting	No Results Available	Lymphoma|Relapsed/Refractory T-cell Lymphomas	Drug: Romidepsin|Drug: Bortezomib|Drug: duvelisib	Stanford University Medical Center, Stanford, California, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Washington School of Medicine in St. Louis, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memoral Sloan Kettering Cancer Center Basking Ridge (Limited protocol activities), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Commack (Limitied protocol activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (Limited protocol activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau (Limited protocol activities), Uniondale, New York, United States	https://ClinicalTrials.gov/show/NCT02783625
61	CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.	Recruiting	No Results Available	Hodgkin Lymphoma, Adult|T Cell Lymphoma	Biological: HSP-CAR30	Hospital Santa Creu i Sant Pau, Barcelona, Spain	https://ClinicalTrials.gov/show/NCT04653649
62	Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas	Recruiting	No Results Available	T-cell Non-Hodgkin Lymphoma|Lymphoma, Extranodal NK-T-Cell	Drug: Busulfan|Drug: Fludarabine	Dong-A University, Busan, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02859402
63	Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy	Recruiting	No Results Available	Peripheral T-cell Lymphoma	Drug: Azacitidine|Drug: Chidamide	Shanghai Ruijin Hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT04480125
64	CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma	Recruiting	No Results Available	Relapsed T-Cell Lymphoma|Refractory T-Cell Lymphoma|Non Hodgkin Lymphoma	Drug: CPI 613|Drug: Bendamustine	Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States	https://ClinicalTrials.gov/show/NCT04217317
65	Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma	Recruiting	No Results Available	Lymphoma, T-Cell	Drug: Durvalumab|Drug: Pralatrexate|Drug: Romidepsin|Drug: 5-Azacitidine	Center for Lymphoid Malignancies at CUMC, New York, New York, United States|University of Bologna, Bologna, Italy|Samsung Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03161223
66	Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides	Recruiting	No Results Available	Peripheral T Cell Lymphoma|Transformed Mycosis Fungoides	Drug: AFM13	University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center), Birmingham, Alabama, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|University of California Los Angeles (UCLA) Health, Los Angeles, California, United States|Emory University Clinic/Winship Cancer Institute, Atlanta, Georgia, United States|University of Michigan Health   Rogel Cancer Center, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Center for Lymphoid Malignancies, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States|Royal Adelaide Hospital, Adelaide, Australia|Flinders Medical Centre, Bedford Park, Australia|Monash Health-Monash Medical Centre, Clayton, Australia|Concord Repatriation General Hospital, Concord, Australia|Gosford Hospital, Gosford, Australia|Linear Clinical Research, Nedlands, Australia|Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux, France|Centre Hospitalier Universitaire de Brest, Brest, France|CHD Vendée, La Roche Sur Yon, France|Institut Gustave Roussy, Villejuif, France|Kliniken Essen Sued - Evangelisches Krankenhaus Essen-Werden gGmbH, Essen, Germany|University Hospital Leipzig, Leipzig, Germany|Universitaetsmedizin Mainz, Mainz, Germany|Rotkreuzklinikum Muenchen, Muenchen, Germany|Ist.Ematologia E Oncologia Medica L.E A.Seragnoli, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia, Brescia, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy|Azienda Ospedaliera Niguarda Ca' Granda, Milano, Italy|Azienda Unita Sanitaria Locale di Ravenna - Ospedale S. Maria delle Croci di Ravenna, Ravenna, Italy|Chonbuk National University Hospital, Jeonju, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of|Szpitale Pomorskie Sp. z o.o.. Szpital Morski im. PCK, Oddzial Hematologii i Transplantologii Szpiku, Gdynia, Poland|Pratia MCM Krakow, Kraków, Poland|Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego, Warsaw, Poland|Instytut Hematologii i Transfuzjologii, Klinika Hematologii, Warsaw, Poland|Republic Hospital n.a. V.A. Baranov, Petrozavodsk, Russian Federation|First State Saint-Petersburg Pavlov Medical University, Saint Petersburg, Russian Federation|Saratov State Medical University, Saratov, Russian Federation|GUZ Leningrad Regional Clinical Hospital, St. Petersburg, Russian Federation|Russian Research Institute of Hematology and Transfusiology of the Federal Biomedical Agency, St. Petersburg, Russian Federation|Regional Clinical Hospital, Tula, Russian Federation|Duran I Reynals Hospital Catalan Institute Of Oncology, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Institut Catala d'Oncologia Badalona, Hospital Germans Trias I Pujol, Barcelona, Spain|Institut Catala d' Oncologia Girona, Girona, Spain|Hospital Universitario 12 de Octubre-Centro de Actividades Ambulatorias, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Institut Catala d'Oncologia Tarragona, Tarragona, Spain|Ankara University Faculty of Medicine, Department of Internal Diseases, Hematology Division, Ankara, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim Arastirma Hastanesi Hematoloji Klinigi Ankara, Ankara, Turkey|Gazi University Faculty of Medicine, Department of Internal Diseases, Ankara, Turkey|Sağlık Bilimleri Üniversitesi Gülhane Eğitim ve Araştırm Hastanesi, Ankara, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi Ic Hastaliklari Anabilim Dali Hematoloji Bilim Dali Fatih, Istanbul, Turkey|Ege University Medical Faculty, İzmir, Turkey|Kocaeli University Faculty of Medicine, Department of Internal Diseases, Hematology Division, İzmit, Turkey|Ondokuz Mayis Universitesi Tip Fakultesi Saglik Uyg. ve Egitim Merkezi, Samsun, Turkey|Tekirdag Namik Kemal Universitesi Saglik Uygulama ve Arastirma Hastanesi, Tekirdag, Turkey|KaradenizTeknik Universitesi Tip Fakultesi Farabi Hastanesi, Trabzon, Turkey	https://ClinicalTrials.gov/show/NCT04101331
67	CTCL Directed Therapy	Recruiting	No Results Available	Lymphoma, T-Cell, Cutaneous	Drug: Doxycycline|Drug: Imiquimod	James J Peters Bronx Veterans Affairs Medical Center, Bronx, New York, United States	https://ClinicalTrials.gov/show/NCT03116659
68	Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)	Recruiting	No Results Available	Relapsed/Refractory Peripheral T-Cell Lymphoma|Adult T Cell Leukemia/Lymphoma	Drug: Valemetostat Tosylate	National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Cancer Center Hospital, Chuo Ku, Tokyo, Japan	https://ClinicalTrials.gov/show/NCT04703192
69	Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients	Recruiting	No Results Available	Non-Hodgkin's Lymphoma (NHL)|Peripheral T Cell Lymphoma (PTCL)	Biological: Ex-vivo expanded allogeneic γδT cells	Institute of Hematology & Blood Disease Hospital, Tianjin, Tianjin, China	https://ClinicalTrials.gov/show/NCT04696705
70	PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma	Not yet recruiting	No Results Available	NK/T-cell Lymphoma	Drug: SHR1210		https://ClinicalTrials.gov/show/NCT03701022
71	A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma	Recruiting	No Results Available	Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)	Drug: ASTX660	Yamagata University Hospital, Yamagata, Japan	https://ClinicalTrials.gov/show/NCT04362007
72	Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease	Recruiting	No Results Available	Cutaneous T-Cell Lymphoma, Unspecified|Chronic Graft Versus Host Disease in Skin	Drug: ECP with 5-aminolevulinic acid	St Olavs Hospital, Trondheim, Norway	https://ClinicalTrials.gov/show/NCT03109353
73	Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma	Recruiting	No Results Available	Peripheral T-Cell Lymphoma|Lenalidomide|CHOP	Drug: Lenalidomide|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone	2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04922567
74	A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)	Recruiting	No Results Available	Hodgkin Disease|Peripheral T Cell Lymphoma	Drug: brentuximab vedotin|Drug: bendamustine|Drug: dacarbazine|Drug: nivolumab	University of Alabama at Birmingham, Birmingham, Alabama, United States|University of South Alabama - Mitchell Cancer Institute, Mobile, Alabama, United States|Alaska Urological Institute, Anchorage, Alaska, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|Arizona Cancer Center / University of Arizona, Tucson, Arizona, United States|Highlands Oncology Group, Springdale, Arkansas, United States|Providence St Joseph Medical Center, Burbank, California, United States|City of Hope National Medical Center, Duarte, California, United States|Wilshire Oncology Medical Group Inc., Pomona, California, United States|Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States|Florida Cancer Affiliates, Trinity, Florida, United States|IACT Health, Columbus, Georgia, United States|Georgia Cancer Specialists / Northside Hospital Cancer Institute, Sandy Springs, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Illinois Cancer Specialists / Advocate Lutheran General Hospital, Niles, Illinois, United States|American Oncology Partners of Maryland, P.A., Bethesda, Maryland, United States|Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States|Minnesota Oncology Hematology P.A., Minneapolis, Minnesota, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Morristown Medical Center/ Carol G. Simon Cancer Center, Morristown, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Columbia University Medical Center, New York, New York, United States|James P. Wilmot Cancer Center / University of Rochester Medical Center, Rochester, New York, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|James Cancer Hospital / Ohio State University, Columbus, Ohio, United States|Willamette Valley Cancer Institute/Oncology Assc of Oregon, Eugene, Oregon, United States|Northwest Cancer Specialists, P.C., Tigard, Oregon, United States|Prisma Health-Upstate, Greenville, South Carolina, United States|Arlington Cancer Center, Arlington, Texas, United States|Texas Oncology - Bedford, Bedford, Texas, United States|Texas Oncology - Presbyterian Cancer Center Dallas, Dallas, Texas, United States|Texas Oncology - Denton South, Denton, Texas, United States|Texas Oncology - Fort Worth 12th Avenue, Fort Worth, Texas, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, United States|Houston Methodist Cancer Center, Houston, Texas, United States|Texas Oncology - Longview, Longview, Texas, United States|Texas Oncology - McAllen, McAllen, Texas, United States|Texas Oncology - Seton Williamson, Round Rock, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care, Salem, Virginia, United States|Shenandoah Oncology P.C., Winchester, Virginia, United States|Benaroya Research Institute/Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Carbone Cancer Center / University of Wisconsin, Madison, Wisconsin, United States|University of Alberta / Cross Cancer Institute, Edmonton, Alberta, Canada|London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada|CIUSSS de L'Est de l'lle de Montreal / installation Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada	https://ClinicalTrials.gov/show/NCT01716806
75	A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression	Recruiting	No Results Available	Peripheral T-cell Lymphoma	Drug: brentuximab vedotin|Drug: cyclophosphamide|Drug: doxorubicin|Drug: prednisone	University of Alabama at Birmingham, Birmingham, Alabama, United States|Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States|Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States|Illinois Cancer Specialists / Advocate Lutheran General Hospital, Niles, Illinois, United States|Tulane University Hospital and Clinic, New Orleans, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Cleveland Clinic, The, Cleveland, Ohio, United States|Oncology Hematology Care, Fairfield, Ohio, United States|University of Tennessee, Knoxville, Tennessee, United States|Texas Oncology - Amarillo, Amarillo, Texas, United States|Texas Oncology - Austin Midtown, Austin, Texas, United States|Texas Oncology - Fort Worth 12th Avenue, Fort Worth, Texas, United States|Texas Oncology - Tyler, Longview, Texas, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|Virginia Oncology Associates - Virginia Beach, Virginia Beach, Virginia, United States	https://ClinicalTrials.gov/show/NCT04569032
76	Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL	Recruiting	No Results Available	Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type	Drug: CAPA indution immunotherapy	Shanghai Eye Ear Nose and Throat Hospital, Fudan University, Shanghai, Shanghai, China|Department of Hematology, Xinhua hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04366128
77	Mogamulizumab Q4week Dosing in Participants With R/R CTCL	Not yet recruiting	No Results Available	Cutaneous T-Cell Lymphoma, Relapsed|Cutaneous T-Cell Lymphoma Refractory	Drug: Mogamulizumab		https://ClinicalTrials.gov/show/NCT04745234
78	Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma	Recruiting	No Results Available	T Cell Non-Hodgkin Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Angioimmunoblastic T-cell Lymphoma|Anaplastic Large Cell Lymphoma	Biological: AUTO4	Vall d'Hebron Institute of Oncology, Barcelona, Spain|Queen Elizabeth University Hospital, Glasgow, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom|Manchester Royal Infirmary Hospital, Manchester, United Kingdom|Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom	https://ClinicalTrials.gov/show/NCT03590574
79	Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL	Recruiting	No Results Available	Peripheral T-cell Lymphoma	Drug: CHOP|Drug: fractionated ICED	Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02445404
80	Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma	Recruiting	No Results Available	Anaplastic Large Cell Lymphoma|Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma	Other: Laboratory Biomarker Analysis|Drug: Romidepsin|Drug: Venetoclax	City of Hope Medical Center, Duarte, California, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States	https://ClinicalTrials.gov/show/NCT03534180
81	A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)	Recruiting	No Results Available	Cutaneous T Cell Lymphoma|Mycosis Fungoides/Sezary Syndrome	Drug: Pembrolizumab|Radiation: Radiotherapy	Guys & St Thomas's NHS Foundation Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom	https://ClinicalTrials.gov/show/NCT03385226
82	Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL	Not yet recruiting	No Results Available	Extranodal NK/T-cell Lymphoma	Drug: Basiliximab|Drug: Pegaspargase		https://ClinicalTrials.gov/show/NCT04337593
83	Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma	Recruiting	No Results Available	Immune Checkpoint Inhibitor|Chemotherapy Effect|Epigenetic Disorder|NK/T-cell Lymphoma of Nasal Cavity	Drug: Anti-PD-1 antibody+Peg-Asparaginase+Chidamide	Hunan Cancer Hospital, Changsha, Hunan, China	https://ClinicalTrials.gov/show/NCT04414969
84	Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL	Not yet recruiting	No Results Available	Angioimmunoblastic T-cell Lymphoma	Drug: Sintilimab|Drug: Chidamide	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04831710
85	Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)	Recruiting	No Results Available	Relapsed or Refractory Peripheral T Cell Lymphoma	Drug: AZD4205	Yale Cancer Center, New Haven, Connecticut, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Beijing Cancer Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|Sichuan University - West China Hospital, Chengdu, China|The First Affiliated Hospital of Zhejiang University, Hangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Fudan University Shanghai Cancer Center, Shanghai, China|Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China|The First Affiliated Hospital of Soochow University, Suzhou, China|Wuhan Union Hospital, Wuhan, China|Henan Cancer Hospital, Zhengzhou, China|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Keimyung University Dongsan Hospital, Daegu, Korea, Republic of|National Cancer Center, Goyang, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT04105010
86	Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma	Not yet recruiting	No Results Available	T-Cell Lymphoma|Peripheral T-Cell Lymphoma Refractory|Cutaneous T-Cell Lymphoma Refractory|Cutaneous T-Cell Lymphoma Recurrent|Peripheral T-Cell Lymphoma Recurrent	Biological: LB1901		https://ClinicalTrials.gov/show/NCT04712864
87	CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia	Recruiting	No Results Available	T-lymphoblastic Lymphoma|NK/T Cell Lymphoma|Acute Lymphocytic Leukemia	Drug: CD7 CAR-T cells infusion	First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China	https://ClinicalTrials.gov/show/NCT04004637
88	Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma	Recruiting	No Results Available	Peripheral T-cell Lymphomas|Lymphoproliferative Disorders|Immune System Diseases	Drug: IOC|Drug: GVHD prophylaxis|Drug: RIC|Procedure: allo HCT|Drug: mRIC|Drug: ATL-RIC	National Institutes of Health Clinical Center, Bethesda, Maryland, United States|National Marrow Donor Program, Minneapolis, Minnesota, United States	https://ClinicalTrials.gov/show/NCT03922724
89	GPED Regimen for Relapsed/Refractory or Advanced ENKTCL	Recruiting	No Results Available	Extranodal NK/T-cell Lymphoma, Nasal Type	Drug: gemcitabin|Drug: Pegaspargase|Drug: Etoposide|Drug: Dexamethasone	Beijing Tongren Hospital, Beijing, China	https://ClinicalTrials.gov/show/NCT04405375
90	A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)	Recruiting	No Results Available	T Cell Lymphoma	Biological: CTX130	Research Site 2, Duarte, California, United States|Research Site 5, Stanford, California, United States|Research Site 4, Miami, Florida, United States|Research Site 8, Bronx, New York, United States|Research Site 9, New York, New York, United States|Research Site 1, Houston, Texas, United States|Research Site 6, Salt Lake City, Utah, United States|Research Site 3, Sydney, New South Wales, Australia|Research Site 7, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT04502446
91	Tofacitinib Combined With Chidamide in R/R ENKTCL	Not yet recruiting	No Results Available	Extranodal NK/T-cell Lymphoma	Drug: tofacitinib|Drug: chidamide	West China Hospital of Sichuan University, Chengdu, Sichuan, China	https://ClinicalTrials.gov/show/NCT03598959
92	A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma	Recruiting	No Results Available	Hodgkin Lymphoma|Peripheral T Cell Lymphoma|Anaplastic Large Cell Lymphoma	Drug: brentuximab vedotin	Pacific Cancer Medical Center, Anaheim, California, United States|Memorial Cancer Institute, Pembroke Pines, Florida, United States|Northwest Oncology and Hematology/AMITA, Elk Grove Village, Illinois, United States|Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Tulane University Hospital and Clinic, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States|Saint Louis University, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Summit Medical Group, Florham Park, New Jersey, United States|Medical University of South Carolina/Hollings Cancer Center, Charleston, South Carolina, United States|Texas Oncology - Fort Worth, Dallas, Texas, United States|Texas Oncology - Fort Worth 12th Avenue, Fort Worth, Texas, United States|The Center for Cancer and Blood Disorders: Fortworth, Fort Worth, Texas, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, United States|Houston Methodist Cancer Center, Houston, Texas, United States|Texas Oncology - San Antonio Medical Center, San Antonio, Texas, United States	https://ClinicalTrials.gov/show/NCT03947255
93	Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL	Not yet recruiting	No Results Available	Peripheral T Cell Lymphoma	Drug: Mitoxantrone Hydrochloride Liposome Injection|Drug: Chidamide	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04668690
94	Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL	Not yet recruiting	No Results Available	Peripheral T-cell Lymphoma	Drug: Sintilimab|Drug: Chidamide|Drug: Azacidine	Beijing, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04052659
95	Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL	Not yet recruiting	No Results Available	Extranodal NK/T-cell Lymphoma, Nasal Type	Drug: Pegaspargase|Drug: Anti-PD-1 monoclonal antibody|Radiation: Definitive intensity-modulated radiotherapy (IMRT)	Sun Yat-sen University Cancer Center, Guangzhou, Please Select, China	https://ClinicalTrials.gov/show/NCT04676789
96	CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.	Recruiting	No Results Available	Enteropathy Associated T-cell Lymphoma	Drug: Brentuximab Vedotin	Hopital Necker - Enfants malades, Paris, France	https://ClinicalTrials.gov/show/NCT03217643
97	CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies	Recruiting	No Results Available	T Cell Lymphoma in Relapse|Refractory T-Cell Lymphoma	Biological: CD4 CAR T cells	Peking University Shenzhen Hospital, Shenzhen, Guangdong, China|Chengdu Military General Hospital, Chengdu, Sichuan, China	https://ClinicalTrials.gov/show/NCT04162340
98	Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma	Recruiting	No Results Available	Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type|Early Stage|Anlotinib|Peg-aspargase|Sintilimab|Phase Two|Open	Drug: Sintilimab	Sun Yat-Sen University Cancer Center, Guandong, Guangdong, China|Guangxi Medicanl Universitu Affiliated Tumor Hospital, Nanning, Guangxi, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|Hunan Cancer Hospital, Changsha, Hunan, China|West China Hospital.Sichuan University, Chengdu, Sichuan, China|Yunan Cancer Hospital, Kunming, Yunnan, China	https://ClinicalTrials.gov/show/NCT03936452
99	A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)	Recruiting	No Results Available	CTCL	Drug: ABT-199 (venetoclax)	Yale New Haven Hospital / Smilow Cancer Center, New Haven, Connecticut, United States	https://ClinicalTrials.gov/show/NCT04171791
100	A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)	Recruiting	No Results Available	PTCL	Drug: Azacytidine|Drug: Romidepsin|Drug: Belinostat|Drug: Pralatrexate|Drug: Gemcitabine	University of Virginia, Charlottesville, Virginia, United States	https://ClinicalTrials.gov/show/NCT04747236
101	Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma	Not yet recruiting	No Results Available	Recurrent Adult T-Cell Leukemia/Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Adult T-Cell Leukemia/Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Mogamulizumab|Biological: Natural Killer Cell Therapy|Other: Quality-of-Life Assessment|Other: Questionnaire Administration	Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States	https://ClinicalTrials.gov/show/NCT04848064
102	Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma	Not yet recruiting	No Results Available	Adult T-cell Leukemia/Lymphoma|Extranodal NK-/T-cell Lymphoma, Nasal Type|Enteropathy-Associated T-Cell Lymphoma|Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma|Hepatosplenic T-cell Lymphoma	Drug: CC-486 (5-azacitidine)|Drug: Duvelisib|Drug: Romidepsin|Drug: Doxorubicin	National Institutes of Health Clinical Center, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT04639843
103	Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma	Not yet recruiting	No Results Available	Angioimmunoblastic T-cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Follicular T-Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma|Nodal Peripheral T-Cell Lymphoma With TFH Phenotype|Peripheral T-Cell Lymphoma, Not Otherwise Specified	Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Etoposide|Drug: Duvelisib|Drug: Oral azacitidine		https://ClinicalTrials.gov/show/NCT04803201
104	Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma	Recruiting	No Results Available	Lymphoma	Drug: Chidamide	National Cancer Center, Cancer Hospital, Chinese Academy of Medical Scienses, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04511351
105	Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma	Not yet recruiting	No Results Available	LYMPHOMA	Drug: Durvalumab|Drug: Lenali	National University Hospital Singapore, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore|Raffles Hospital Singapore, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT03054532
106	Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL	Not yet recruiting	No Results Available	Treatment-naïve|Peripheral T Cell Lymphoma	Drug: Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|Drug: Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04548700
107	Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas	Recruiting	No Results Available	Anaplastic Large Cell Lymphoma|Nodal Peripheral T-Cell Lymphoma With TFH Phenotype|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Angioimmunoblastic T-Cell Lymphoma|Recurrent Enteropathy-Associated T-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Hepatosplenic T-Cell Lymphoma|Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma|Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma|Recurrent Mycosis Fungoides|Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Anaplastic Large Cell Lymphoma|Refractory Angioimmunoblastic T-Cell Lymphoma|Refractory Enteropathy-Associated T-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Hepatosplenic T-Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified|Subcutaneous Panniculitis-Like T-Cell Lymphoma	Biological: Pembrolizumab|Drug: Pralatrexate	City of Hope Medical Center, Duarte, California, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States	https://ClinicalTrials.gov/show/NCT03598998
108	A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)	Recruiting	No Results Available	T-cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepato-splenic T-cell Lymphoma|Adult T-cell Leukemia/Lymphoma|Enteropathy Associated T-cell Lymphoma|NK T-cell Lymphoma	Drug: Brentuximab vedotin	University of Michigan, Ann Arbor, Michigan, United States|Wayne State University, Karmanos Cancer Institute, Detroit, Michigan, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States	https://ClinicalTrials.gov/show/NCT02588651
109	Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients	Recruiting	No Results Available	Experimental Tumor	Drug: Chidamide|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Etoposide|Drug: Prednisone	Beijing Cancer Hospital, Beijing, China	https://ClinicalTrials.gov/show/NCT03617432
110	Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas	Not yet recruiting	No Results Available	Recurrent Anaplastic Large Cell Lymphoma|Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Transformed Mycosis Fungoides|Refractory Anaplastic Large Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Transformed Mycosis Fungoides|T-Cell Non-Hodgkin Lymphoma	Drug: Parsaclisib|Drug: Romidepsin	Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States	https://ClinicalTrials.gov/show/NCT04774068
111	Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma	Not yet recruiting	No Results Available	T-cell Lymphoma|Cutaneous/Peripheral T-Cell Lymphoma|Peripheral T-cell Lymphoma|Peripheral T-Cell Lymphoma, Not Classified|Primary Cutaneous T-cell Lymphoma|Cutaneous T-Cell Lymphoma, Unspecified|Cutaneous T-cell Lymphoma|Follicular T-Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Sézary's Disease|Mycosis Fungoides	Drug: Fenretinide	Rush University Medical Center, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT04234048
112	Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma	Not yet recruiting	No Results Available	Lymphoma, Extranodal NK-T-Cell	Drug: Pembrolizumab|Radiation: Involved Field Radiation Therapy	Shanghai Rui-Jin Hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT04417166
113	Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma	Not yet recruiting	No Results Available	Recurrent Angioimmunoblastic T-Cell Lymphoma|Recurrent Enteropathy-Associated T-Cell Lymphoma|Recurrent Follicular T-Cell Lymphoma|Recurrent Hepatosplenic T-Cell Lymphoma|Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype|Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified|Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma|Refractory Angioimmunoblastic T-Cell Lymphoma|Refractory Enteropathy-Associated T-Cell Lymphoma|Refractory Follicular T-Cell Lymphoma|Refractory Hepatosplenic T-Cell Lymphoma|Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma	Drug: Brentuximab Vedotin|Biological: Pembrolizumab	Northwestern University, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT04795869
114	PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma	Recruiting	No Results Available	Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type	Drug: pegaspargase|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Methotrexate|Drug: Dexamethasone|Drug: Thalidomide	Department of Medical Oncology, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02085655
115	Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma	Recruiting	No Results Available	Lymphomatoid Papulosis|Primary Cutaneous Anaplastic Large Cell Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage I Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage II Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma	Drug: Brentuximab Vedotin|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide	Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States	https://ClinicalTrials.gov/show/NCT03409432
116	Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma	Recruiting	No Results Available	Adult T-Cell Leukemia/Lymphoma|Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Angioimmunoblastic T-Cell Lymphoma|Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma|Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma|Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Hepatosplenic T-Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified	Drug: Brentuximab Vedotin|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Drug: Etoposide Phosphate|Other: Laboratory Biomarker Analysis|Drug: Prednisone	City of Hope Comprehensive Cancer Center, Duarte, California, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|M D Anderson Cancer Center, Houston, Texas, United States|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada	https://ClinicalTrials.gov/show/NCT03113500
117	Rituximab Combined With Chidamide and Lenalidomide for r/r AITL	Recruiting	No Results Available	Angioimmunoblastic T-cell Lymphoma|Chemotherapy Effect|Chemotherapeutic Toxicity	Drug: Rituximab	Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04319601
118	Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma	Recruiting	No Results Available	Folliculotropic Mycosis Fungoides|Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified|Sezary Syndrome|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma	Biological: Durvalumab|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide	City of Hope Medical Center, Duarte, California, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT03011814
119	Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL	Recruiting	No Results Available	Mycosis Fungoides|Lymphoma, T-Cell, Cutaneous|Sézary Syndrome	Drug: Naloxone Hydrochloride Lotion, 0.5%|Drug: Placebo Lotion	University of Alabama Medical Center, Birmingham, Alabama, United States|Mayo Clinic, Scottsdale, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|City of Hope, Duarte, California, United States|Stanford University, Palo Alto, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|USSF Health Morsani Center for Advanced Healthcare, Tampa, Florida, United States|Cleveland Clinic Indian River Hospital, Vero Beach, Florida, United States|Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|The University of Chicago Medicine, Chicago, Illinois, United States|Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Massachusetts General Hospital CURTIS, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|St. Louis University Dermatology, Saint Louis, Missouri, United States|Washington University School of Medicine St. Louis, Saint Louis, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Columbia University Medical Center, New York, New York, United States|Stony Brook Dermatology, Stony Brook, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Ohio State University, James and Solove Research and Cancer Hospital, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Jefferson Dermatology Associates, Philadelphia, Pennsylvania, United States|UPMC Department of Dermatology, Pittsburgh, Pennsylvania, United States|Vanderbilt Dermatology, Nashville, Tennessee, United States|University of Texas South Western Medical Center, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States|University of Washington / Seattle Cancer Care Alliance (SCCA), Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT02811783
120	Study of Photopheresis in the Treatment of Erythrodermic MF and SS	Not yet recruiting	No Results Available	Lymphoma, T-Cell, Cutaneous|Mycosis Fungoides/Sezary Syndrome	Drug: Methoxsalen|Device: THERAKOS CELLEX Photopheresis System	UniversitaetsSpital Zurich - Division of Dermatology, Zürich, Switzerland	https://ClinicalTrials.gov/show/NCT03563040
121	Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy	Not yet recruiting	No Results Available	Natural Killer/T-cell Lymphoma|Relapsed Natural Killer/T-cell Lymphoma|Refractory Natural Killer/T-cell Lymphoma	Drug: Isatuximab|Drug: Cemiplimab		https://ClinicalTrials.gov/show/NCT04763616
122	Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.	Not yet recruiting	No Results Available	Mycosis Fungoides	Combination Product: Pembrolizumab administered using the Sofusa® DoseConnect™		https://ClinicalTrials.gov/show/NCT04118868
123	Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies	Recruiting	No Results Available	T-cell Acute Lymphoblastic Leukemia|T-cell Non-Hodgkin Lymphoma	Drug: anti-CD5 CAR T cells	Peking University Shenzhen Hospital, Shenzhen, Guangdong, China	https://ClinicalTrials.gov/show/NCT04594135
124	Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL	Not yet recruiting	No Results Available	Extranodal NK/T-cell Lymphoma, Nasal Type	Drug: Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase|Drug: Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase|Drug: Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase		https://ClinicalTrials.gov/show/NCT04509466
125	Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma	Recruiting	No Results Available	Hematopoietic Cell Transplantation Recipient|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma	Procedure: Allogeneic Bone Marrow Transplantation|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Biological: Anti-Thymocyte Globulin|Drug: Busulfan|Drug: Clofarabine|Drug: Gemcitabine Hydrochloride|Drug: Mycophenolate Mofetil|Procedure: Peripheral Blood Stem Cell Transplantation|Other: Pharmacological Study|Biological: Rituximab|Drug: Tacrolimus	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01701986
126	ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy	Recruiting	No Results Available	Aggressive Non-hodgkin Lymphoma (aNHL)|Lymphoma, B-Cell|Lymphoma, T-Cell	Drug: High dose chemotherapy before allogeneic stem cell transplantation (alloSCT)|Procedure: Bone marrow histology|Diagnostic Test: clinical and laboratory parameters|Diagnostic Test: PET-CT or CT	HELIOS Klinik Berlin-Buch, Klinik für Hämatologie und Stammzelltransplantation, Berlin, Brandenburg, Germany|Klinikum Augsburg, Medizinische Klinik II, Augsburg, Germany|Medizinisches Universitätsklinikum, Bochum, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Medzinische Klinik I, Dresden, Germany|Universitäsklinikum Düsseldorf, Düsseldorf, Germany|Universitätsmedizin Göttingen Klinik für Hämatologie/Med. Onkologie, Göttingen, Germany|Universitätsklinikum Halle, Halle, Germany|Universitätsklinikum Hamburg-Eppendorf, Zentrum für Onkologie, Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation, Hamburg, Germany|Universitätsklinikum Heidelberg, Medizinische Klinik, Innere Medizin V, Heidelberg, Germany|Universitätsklinikum Jena, Klinik für Innere Medizin, Abtl. Hämatologie und Innternistische Onkologie, Jena, Germany|Universitätsklinikum Münster, KMT-Zentrum/ Med. Klinik A, Münster, Germany|Klinikum Stuttgart, Stuttgart, Germany	https://ClinicalTrials.gov/show/NCT04121507
127	Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)	Recruiting	No Results Available	Mycosis Fungoides|Sezary Syndrome|Lymphoma, T-Cell, Cutaneous	Drug: resminostat|Drug: Placebo	Medizinische Universität Graz, Graz, Austria|Medizinische Universität Wien, Wien, Austria|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Universitaire Ziekenhuizen, Leuven, Belgium|Centre Hospitalier Universitaire (CHU) de Bordeaux - Hôpital Saint-André, Bordeaux, France|CHU Estaing, Clermont-Ferrand, France|Centre Hospitalier Lyon-Sud, Lyon, France|Chu Paris-Gh St-Louis Lariboisiere F.Widal Hopital, Paris, France|Hopital Robert Debre - CHU de Reims, Reims, France|Universitätsklinikum Aachen, Aachen, Germany|Charité - Universitaetsmedizin Berlin, Berlin, Germany|Universitaetsklinikum Bochum - St. Josef-Hospital, Bochum, Germany|Elbekliniken Buxtehude, Buxtehude, Germany|Uniklinik Köln, Cologne, Germany|Klinikum Dortmund, Dortmund, Germany|Universitaetsklinikum Dresden, Dresden, Germany|Helios Klinikum Erfurt, Erfurt, Germany|Universitaetsklinikum Essen, Essen, Germany|SRH Wald-Klinikum Gera, Gera, Germany|Universitaetsklinikum Greifswald, Greifswald, Germany|Universitätsmedizin Göttingen, Göttingen, Germany|Universitaetsklinikum Halle, Halle (Saale), Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany|Städtisches Klinikum Karlsruhe, Karlsruhe, Germany|Universitaetsklinikum Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany|HELIOS Klinikum, Krefeld, Germany|Klinikum der Stadt Ludwigshafen am Rhein, Ludwigshafen am Rhein, Germany|Universitätsklinikum Schleswig-Holstein, Lübeck, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany|Universitätsklinikum Mannheim, Mannheim, Germany|Johannes Wesling Klinikum Minden, Minden, Germany|Ludwig-Maximilians-Universität (LMU), München, Germany|Universitäts-Hautklinik Tübingen, Tübingen, Germany|Universitätsklinikum Ulm, Ulm, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|ATTIKON Hospital and Cutaneous Lymphoma Clinic, Athens, Greece|Policlinico S.Orsola-Malpighi, Ematologia, Bologna, Italy|Policlinico S.Orsola-Malpighi, Bologna, Italy|Universita Di Firenze, Firenze, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|Universita Cattolica del Sacro Cuore, Roma, Italy|IFO San Gallicano, Rome, Italy|Ospedale Molinette, Turin, Italy|Niigata University Medical and Dental Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Tohoku University Hospital, Sendai, Japan|Hamamatsu University School of Medicine, Shizuoka, Japan|University of Tsukuba Hospital, Tsukuba, Japan|Leids Universitair Medisch Centrum (LUMC), Leiden, Netherlands|Centrum Onkologii, Bydgoszcz, Poland|Medical University of Gdansk, Gdansk, Poland|SP ZOZ Szpital Uniwersytecki w Krakowie, Kraków, Poland|Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warsaw, Poland|Katedra I Klinika Dermatologii, Wrocław, Poland|Uniwersytecki Szpital Kliniczny im. WAM - CSW, Łódź, Poland|Hospital Del Mar, Barcelona, Spain|Hospital Duran i Reynals, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Uni. Nuestra Senora de Candelaria, Tenerife, Spain|Hospital General Universitario, Valencia, Spain|Inselspital, Universitätsspital Bern, Bern, Switzerland|Centre hospitalier universitaire vaudois (CHUV), Lausanne, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|University Hospital, Birmingham, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|St John's Institute Of Dermatology - Guy's & St Thomas' Nhs Foundation Trust, London, United Kingdom|Christie Hospital, Manchester, United Kingdom	https://ClinicalTrials.gov/show/NCT02953301
128	VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma	Recruiting	No Results Available	Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Angioimmunoblastic T-Cell Lymphoma|Recurrent Mycosis Fungoides|Recurrent Plasma Cell Myeloma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory Acute Myeloid Leukemia|Refractory Anaplastic Large Cell Lymphoma|Refractory Angioimmunoblastic T-Cell Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Plasma Cell Myeloma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma	Procedure: Computed Tomography|Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Biological: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Drug: Ruxolitinib Phosphate|Procedure: Single Photon Emission Computed Tomography	Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT03017820
129	Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma	Recruiting	No Results Available	T Cell Lymphoma|T-cell Leukemia	Biological: chimeric antigen receptor T cell treatment	Beijing Boren Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04840875
130	Study of Pembrolizumab (MK-3475) in Combination With Romidepsin	Recruiting	No Results Available	Recurrent Anaplastic Large Cell Lymphoma|Recurrent Angioimmunoblastic T-Cell Lymphoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Anaplastic Large Cell Lymphoma|Refractory Angioimmunoblastic T-Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	Biological: Pembrolizumab|Drug: Romidepsin	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT03278782
131	Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas	Recruiting	No Results Available	T-Cell Lymphoma|Indolent B-Cell Lymphoma	Drug: Duvelisib|Procedure: Peripheral blood draw	Washington University School of Medicine, Saint Louis, Missouri, United States	https://ClinicalTrials.gov/show/NCT04331119
132	CD4CAR for CD4+ Leukemia and Lymphoma	Recruiting	No Results Available	T-cell Lymphoma|T-cell Leukemia	Biological: CD4CAR	Stony Brook University, Stony Brook, New York, United States	https://ClinicalTrials.gov/show/NCT03829540
133	Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma	Not yet recruiting	No Results Available	Folliculotropic Mycosis Fungoides|Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Sezary Syndrome|Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8|Transformed Mycosis Fungoides	Procedure: Extracorporeal Photopheresis|Biological: Mogamulizumab|Other: Quality-of-Life Assessment|Other: Questionnaire Administration	City of Hope Medical Center, Duarte, California, United States	https://ClinicalTrials.gov/show/NCT04930653
134	Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies	Not yet recruiting	No Results Available	T-cell Leukemia|T-cell Lymphoma	Biological: CD7 UCAR-T cells|Drug: Fludarabine|Drug: Cytoxan|Drug: Melphalan	Department of Hematology, Xinqiao Hospital, ChongQing, Chongqing, China	https://ClinicalTrials.gov/show/NCT04264078
135	A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies	Recruiting	No Results Available	Relapsed/Refractory T-cell Malignancies|Cutaneous T-Cell Lymphoma|Mature T-cell Malignancies|Peripheral T-Cell Lymphoma	Drug: Romidepsin|Drug: Lenalidomide|Drug: 5-azacitidine|Drug: Dexamethasone	National Institutes of Health Clinical Center, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT04447027
136	T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas	Recruiting	No Results Available	Lymphoma, Large-Cell, Anaplasitc|Enteropathy-Associated T-Cell Lymphoma|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Extranodal NK-T-Cell|Lymphoma, T-Cell, Peripheral	Biological: Anti-CD30-CAR T cells|Drug: Cyclophosphamide|Drug: Fludarabine	National Institutes of Health Clinical Center, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT03049449
137	Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma	Not yet recruiting	No Results Available	Recurrent Aggressive Non-Hodgkin Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Recurrent Transformed B-Cell Non-Hodgkin Lymphoma	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Busulfan|Drug: Clofarabine|Drug: Cyclophosphamide|Drug: Gemcitabine|Drug: Mycophenolate Mofetil|Biological: Rituximab|Drug: Tacrolimus|Drug: Vorinostat	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT04220008
138	Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL	Recruiting	No Results Available	Lymphoma|Immune System Diseases|Immunoproliferative Disorders|Lymphatic Diseases|Lymphoproliferative Disorders|Neoplasms|Cutaneous Lymphoma|Cutaneous Anaplastic Large Cell Lymphoma|Mycosis Fungoides|Sezary Syndrome|Lymphomatoid Papulosis|Cutaneous T Cell Lymphoma|Gray Zone Lymphoma	Biological: ATLCAR.CD30.CCR4 cells|Biological: ALTCAR.CD30 cells|Drug: Bendamustine|Drug: Fludarabine	Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States	https://ClinicalTrials.gov/show/NCT03602157
139	Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies	Recruiting	No Results Available	Peripheral T-cell Lymphoma NOS|Mycosis Fungoides|Sezary Syndrome|Anaplastic Large Cell Lymphoma	Drug: rhIL-15|Biological: Avelumab	National Institutes of Health Clinical Center, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT03905135
140	Autologous Cells Derived Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies	Recruiting	No Results Available	T-Cell Lymphocytic Leukemia|T-Cell Chronic Lymphocytic Leukemia|T Cell Non-Hodgkin Lymphoma	Drug: Fludarabine + Cyclophosphamide + CAR7-T Cells	Union Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT04823091
141	Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas	Recruiting	No Results Available	Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type|Classical Hodgkin Lymphoma	Biological: CD30.CAR-EBVST cells	Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT04288726
142	A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies	Not yet recruiting	No Results Available	Peripheral T Cell Lymphoma|Diffuse Large B Cell Lymphoma|Biliary Tract Cancer|Extranodal NK T Cell Lymphoma, Nasal	Biological: STI-3031		https://ClinicalTrials.gov/show/NCT03999658
143	Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides	Recruiting	No Results Available	Mycosis Fungoides|Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Sezary Syndrome	Procedure: Extracorporeal Photopheresis|Biological: Mogamulizumab|Other: Quality-of-Life Assessment	Emory University Hospital, Atlanta, Georgia, United States	https://ClinicalTrials.gov/show/NCT04676087
144	γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)	Recruiting	No Results Available	Non-Hodgkin's Lymphoma|Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma|Chronic Lymphoblastic Leukemia|Peripheral T Cell Lymphoma	Biological: Autologous γδT cells	Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China	https://ClinicalTrials.gov/show/NCT04028440
145	Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment	Recruiting	No Results Available	Recurrent Mycosis Fungoides|Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Sezary Syndrome|Refractory Mycosis Fungoides|Refractory Mycosis Fungoides and Sezary Syndrome|Refractory Sezary Syndrome|Sezary Syndrome|Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8	Biological: Magrolimab|Biological: Mogamulizumab	Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Stanford Cancer Institute Palo Alto, Palo Alto, California, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States	https://ClinicalTrials.gov/show/NCT04541017
146	Romidepsin Maintenance After Allogeneic Stem Cell Transplantation	Recruiting	No Results Available	Cutaneous T-cell Lymphoma|T-Prolymphocytic Leukemia|T-Large Granulocytic Leukemia|T-Lymphoblastic Leukemia/Lymphoma|Peripheral T-Cell Lymphoma	Drug: Romidepsin|Drug: Busulfan|Drug: Fludarabine|Procedure: Stem Cell Transplant|Drug: Thymoglobulin	The Ohio State University Cancer Center, Columbus, Ohio, United States	https://ClinicalTrials.gov/show/NCT02512497
147	Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies	Recruiting	No Results Available	Hematological Malignancies|Multiple Myeloma|Hodgkin's Lymphoma|Cutaneous T Cell Lymphoma	Drug: Tinostamustine	Mayo Clinic, Phoenix, Arizona, United States|Mayo Clinic Cancer Center, Jacksonville, Florida, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Columbia University Medical Center, New York, New York, United States|The University of Texas MDACC, Houston, Texas, United States|CHU de Caen, Caen, France|CHU ESTAING Service de thérapie Cellulaire et hématologique Clinique, Clermont Ferrand, France|CHU Lille Service des Maladies du Sang, Lille, France|CHU de Nantes, Hotel Dieu, Nantes, France|Hopital Haut Leveque, Pessac, France|Centre hospitalier Lyon Sud, Pierre Bénite, France|University Hospital of Ulm, Department of Internal Medicine III, Ulm, Germany|Institute of Hematology "L. A. Seràgnoli", University of Bologna, Bologna, Italy|National Cancer Institute, Fondazione 'G. Pascale', Naples, Italy|VU medisch centrum, Amsterdam, Netherlands|Erasmus MC, Rotterdam, Netherlands|Institut Català d'Oncologia de Barcelona, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Kantonsspital St.Gallen, St.Gallen, Switzerland	https://ClinicalTrials.gov/show/NCT02576496
148	Lenalidomide in Combination With CHOP in Patients With Untreated PTCL	Recruiting	No Results Available	PTCL, NOS|AITL|ALK- ALCL|Phase III-IV ALK+ ALCL|EATL	Drug: Lenalidomide|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisolone	The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT04423926
149	Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma	Recruiting	No Results Available	NK-Cell Lymphoma|NK-Cell Leukemia|Peripheral T Cell Lymphoma	Drug: Methotrexate|Drug: pralatraxate,|Drug: Ifosfamide|Drug: Dexamethasone|Drug: Etoposide|Drug: calaspargase pegol|Drug: cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone|Drug: Brentuximab Vedotin	New York Medical College, Valhalla, New York, United States	https://ClinicalTrials.gov/show/NCT03719105
150	PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma	Recruiting	No Results Available	Treatment Refusal	Drug: Gemcitabine|Drug: etoposide|Drug: Pegaspargase|Radiation: involved-field radiotherapy	Sun Yat-sen University Cancer Center, Guangzhou, Please Select, China	https://ClinicalTrials.gov/show/NCT02705508
151	Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant	Recruiting	No Results Available	Recurrent Diffuse Large B-Cell Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Hodgkin Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma	Drug: Busulfan|Drug: Gemcitabine|Drug: Melphalan|Drug: Olaparib|Procedure: Peripheral Blood Stem Cell Transplantation|Other: Pharmacokinetic Study|Biological: Rituximab|Drug: Vorinostat	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT03259503
152	Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies	Recruiting	No Results Available	Peripheral T Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Anaplastic Lymphoma|Acute T Cell Leukemia|T-lymphoblastic Lymphoma	Drug: anti-TRBC1 CAR-T cell therapy	Xianmin Song, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04828174
153	Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma	Recruiting	No Results Available	Anaplastic Large Cell Lymphoma|Peripheral T Cell Lymphoma|Extranodal NK/T-cell Lymphoma|Diffuse Large B Cell Lymphoma|Primary Mediastinal Large B-Cell Lymphoma (PMBCL)	Drug: CD30.CAR-T	City of Hope, Duarte, California, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|The University of Texas MD Anderson Cancer Centre, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT04526834
154	Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL	Recruiting	No Results Available	Safety and Efficacy	Drug: Sintilimab|Drug: Chidamide	Department of hematology department, Nanfang hospital, Guangzhou, Guangdong, China|Guangdong General Hospital; Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China|Sun Yat-sen University Cancer Center, Guangzhou, China	https://ClinicalTrials.gov/show/NCT03820596
155	Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies	Recruiting	No Results Available	Lymphoid Malignancies|Multiple Myeloma|Lymphoma|Hodgkin Lymphoma|Non-hodgkin Lymphoma	Drug: Pralatrexate|Drug: Romidepsin	Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Columbia University Irving Medical Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT01947140
156	Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency	Recruiting	No Results Available	Aggressive Non-Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Chronic Lymphocytic Leukemia|Diffuse Large B-Cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Hepatosplenic T-Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Mediastinal (Thymic) Large B-Cell Lymphoma|Nasal Type Extranodal NK/T-Cell Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Primary Cutaneous Anaplastic Large Cell Lymphoma|Refractory Anaplastic Large Cell Lymphoma|Small Lymphocytic Lymphoma|Subcutaneous Panniculitis-Like T-Cell Lymphoma	Dietary Supplement: Cholecalciferol|Other: Laboratory Biomarker Analysis	Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States	https://ClinicalTrials.gov/show/NCT01787409
157	Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies	Recruiting	No Results Available	Adult T-Cell Lymphoma/Leukaemia|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|NK/T-cell Lymphoma|Peripheral T Cell Lymphoma|Hodgkin Lymphoma	Genetic: Anti-CD30 CAR T cells	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT04008394
158	Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas	Recruiting	No Results Available	Recurrent Anaplastic Large Cell Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Classic Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Anaplastic Large Cell Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Classic Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified	Biological: Anti-CD30/CD16A Monoclonal Antibody AFM13|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Fludarabine Phosphate|Biological: Genetically Engineered Lymphocyte Therapy	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT04074746
159	Evaluation of Human Immune Responses to Influenza Virus Vaccination in Patients With Lymphoma	Recruiting	No Results Available	Chronic Lymphocytic Leukemia|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma	Biological: Inactivated Influenza Vaccine	Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States	https://ClinicalTrials.gov/show/NCT03501576
160	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	Recruiting	No Results Available	Adenoid Cystic Skin Carcinoma|Adnexal Carcinoma|Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Apocrine Carcinoma|Cylindrocarcinoma|Digital Papillary Adenocarcinoma|Endocrine Mucin-Producing Sweat Gland Carcinoma|Extramammary Paget Disease|Extraocular Cutaneous Sebaceous Carcinoma|Hidradenocarcinoma|Keratoacanthoma|Malignant Sweat Gland Neoplasm|Merkel Cell Carcinoma|Microcystic Adnexal Carcinoma|NK-Cell Lymphoma, Unclassifiable|Papillary Adenocarcinoma|Porocarcinoma|Primary Cutaneous Mucinous Carcinoma|Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory Anaplastic Large Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Merkel Cell Carcinoma|Refractory Mycosis Fungoides|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Skin Squamous Cell Carcinoma|Refractory T-Cell Non-Hodgkin Lymphoma|Sezary Syndrome|Signet Ring Cell Carcinoma|Skin Basal Cell Carcinoma|Skin Basosquamous Cell Carcinoma|Skin Squamous Cell Carcinoma|Spiradenocarcinoma|Squamoid Eccrine Ductal Carcinoma|Squamous Cell Carcinoma of Unknown Primary|Sweat Gland Carcinoma|Trichilemmal Carcinoma|Vulvar Squamous Cell Carcinoma	Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Biological: Talimogene Laherparepvec	Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States|UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States|UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, United States|UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States|Northwestern University, Chicago, Illinois, United States|University of Kansas Clinical Research Center, Fairway, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|University of Kansas Cancer Center - North, Kansas City, Missouri, United States|University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States|University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States	https://ClinicalTrials.gov/show/NCT02978625
161	Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab	Recruiting	No Results Available	B-Cell Prolymphocytic Leukemia|Chronic Lymphocytic Leukemia|Peripheral T-Cell Lymphoma|Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Sezary Syndrome|T-Cell Prolymphocytic Leukemia	Drug: Letermovir	Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States	https://ClinicalTrials.gov/show/NCT04312841
162	CAR-37 T Cells In Hematologic Malignancies	Recruiting	No Results Available	Hematologic Malignancy|Leukemia|Lymphoma|Lymphoma, B-Cell|Lymphoma, T-Cell|Lymphoma, Non-Hodgkin	Biological: CAR-37 T cells	Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT04136275
163	CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study	Recruiting	No Results Available	T Lymphoblastic Leukemia/Lymphoma|Extramedullary NK-T-cell Lymphoma, Nasal Type|Peripheral T-cell Lymphoma, Nonspecific|Angioimmunoblastic T-cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Anaplastic Large Cell Lymphoma, ALK-negative|T-cell Lymphoblastic Leukemia	Biological: T cell injection targeting CD7 chimeric antigen receptor	First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China	https://ClinicalTrials.gov/show/NCT04480788
164	Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies	Recruiting	No Results Available	Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Juvenile Myelomonocytic Leukemia|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Refractory Cytopenia With Multilineage Dysplasia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia	Drug: Fludarabine phosphate|Drug: Thiotepa|Radiation: Total body irradiation|Biological: Therapeutic allogeneic lymphocytes|Drug: Cyclophosphamide|Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT)|Procedure: Peripheral blood stem cell transplantation|Drug: Tacrolimus|Drug: Mycophenolate mofetil	Thomas Jefferson University, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT01760655
165	Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Recruiting	No Results Available	Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent Aggressive Non-Hodgkin Lymphoma|Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Refractory Aggressive Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma|Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma	Radiation: External Beam Radiation Therapy|Biological: Pembrolizumab	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT03210662
166	Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies	Not yet recruiting	No Results Available	CD5+ Relapsed/Refractory Hematopoietic Malignancies|Chronic Lymphocytic Leukemia (CLL)|Mantle Cell Lymphoma (MCL)|Diffuse Large B-cell Lymphoma (DLBCL)|Follicular Lymphoma (FL)|Peripheral T-cell Lymphomas (PTCL)	Biological: CT125A cells|Drug: Cyclophosphamide, fludarabine		https://ClinicalTrials.gov/show/NCT04767308
167	Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma	Recruiting	No Results Available	Lymphoma|Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Lymphoma, T-Cell|Lymphoma, Follicular|Lymphoma, Peripheral T-Cell|Lymphoma, Hodgkin	Drug: OT-82 Dose Escalation|Drug: OT-82 Dose Expansion	University of Alabama at Birmingham, Birmingham, Alabama, United States|City of Hope National Medical Center, Duarte, California, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT03921879
168	A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies	Recruiting	No Results Available	Mantle Cell Lymphoma|Peripheral T-cell Lymphoma (PTCL)|Cutaneous T-cell Lymphoma (CTCL)|Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)|Follicular Lymphoma|Marginal Zone Lymphoma|Hodgkin Lymphoma|Waldenstrom Macroglobulinemia|DLBCL	Drug: L-Bcl-2 antisense oligonucleotide	Georgia Cancer Center, Augusta, Georgia, United States|Sarah Cannon Research Institute/Tennesee Oncology, Nashville, Tennessee, United States|MD Anderson Cancer Research Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT04072458
169	Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma	Recruiting	No Results Available	Advanced Cancer|Gastric Cancer|Breast Cancer|Pancreatic Cancer|Prostate Cancer Metastatic|Colo-rectal Cancer|Solid Tumor|Solid Carcinoma|Solid Carcinoma of Stomach|Cancer of Stomach|Lymphoma|Sarcoma|Cutaneous T Cell Lymphoma|Head and Neck Squamous Cell Carcinoma|Basal Cell Carcinoma|Cutaneous T-cell Lymphoma|Cutaneous Squamous Cell Carcinoma	Drug: GZ17-6.02	HonorHealth Research Institute, Scottsdale, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States	https://ClinicalTrials.gov/show/NCT03775525
170	Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases	Recruiting	No Results Available	Psoriasis|Cutaneous T Cell Lymphoma|Lymphoproliferative Disorders|Eczema|Lichen Planus|Prurigo|Pruritus|Polymorphic Light Eruption|Graft Vs Host Disease|Mastocytosis|Vitiligo	Other: Photo(chemo)therapy	Medical University of Graz, Department of Dermatology, Graz, Styria, Austria	https://ClinicalTrials.gov/show/NCT03340155
171	A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer	Recruiting	No Results Available	Non-small Cell Lung Cancer|Gastric Carcinoma|Gastroesophageal Junction Carcinoma|Classical Hodgkin Lymphoma|Diffuse Large B-cell Lymphoma|Peripheral T-cell Lymphoma|Cutaneous Melanoma|Head and Neck Squamous Cell Carcinoma|Bladder Cancer|Ovarian Cancer|Triple Negative Breast Cancer|Cervical Cancer	Drug: SEA-TGT|Drug: sasanlimab	University of Alabama at Birmingham, Birmingham, Alabama, United States|City of Hope National Medical Center, Duarte, California, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Providence Portland Medical Center, Portland, Oregon, United States|University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Institut Gustave Roussy, Villejuif-Cedex-France, Other, France|Istituto Europeo di Oncologia, Milano, Other, Italy|Hospital Universitario Vall d'Hebron, Barcelona, Other, Spain|The Royal Marsden Hospital (Surrey), Sutton, Other, United Kingdom	https://ClinicalTrials.gov/show/NCT04254107
172	BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)	Recruiting	No Results Available	Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Chronic Lymphocytic Leukemia|Small Lymphocytic Leukemia|B Cell Lymphoma|Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia|Peripheral T Cell Lymphoma	Drug: BR101801 (Phase Ia)|Drug: BR101801 (Phase Ib)	Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul national university hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT04018248
173	A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers	Recruiting	No Results Available	Head and Neck Squamous Cell Carcinoma|Breast Cancer|Sarcoma|Merkel Cell Carcinoma|Cutaneous T-Cell Lymphoma|Melanoma|Renal Cancer|Bladder Cancer|Prostate Cancer|Testicular Cancer|Solid Tumor	Drug: Durvalumab|Drug: Tremelimumab|Drug: Poly ICLC	Research Facility, Atlanta, Georgia, United States|Research Facility, Lebanon, New Hampshire, United States|Research Facility, Buffalo, New York, United States|Research Facility, New York, New York, United States|Research Facility, Cleveland, Ohio, United States|Research Facility, Toledo, Ohio, United States|Research Facility, Charlottesville, Virginia, United States	https://ClinicalTrials.gov/show/NCT02643303
174	A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies	Recruiting	No Results Available	Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Diffuse Large B-cell Lymphoma|Richter Transformation Lymphoma|Burkitt Lymphoma|Lymphoplasmacytoid Lymphoma|T-cell Non-Hodgkin Lymphoma|Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Waldenstrom Macroglobulinemia	Drug: VLS-101 Schedule 1|Drug: VLS-101 Schedule 2|Drug: VLS-101 Schedule 3	City of Hope National Medical Center, Duarte, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|UCLA Department of Medicine - Hematology/Oncology, Los Angeles, California, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Northwell Health/CLL Research and Treatment Program, New Hyde Park, New York, United States|Weill Cornell Medical College - New York - Presbyterian Hospital, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|MD Anderson Cancer Center, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT03833180
175	Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies	Recruiting	No Results Available	B-Cell Non-Hodgkin Lymphoma|Hematopoietic and Lymphoid Cell Neoplasm|Leukemia|Lymphoma|Plasma Cell Myeloma|T-Cell Non-Hodgkin Lymphoma	Biological: Ipilimumab|Drug: Lenalidomide	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01919619
176	Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies	Recruiting	No Results Available	Relapsed or Refractory Haematological Malignancies Including|Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|High Risk Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Richter's Syndrome|B-cell Non-Hodgkin Lymphoma|T-cell Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma|Multiple Myeloma	Drug: AZD4573	Research Site, Aachen, Germany|Research Site, Bonn, Germany|Research Site, Essen, Germany|Research Site, Göttingen, Germany|Research Site, Heidelberg, Germany|Research Site, Rheinland-Pfalz, Germany|Research Site, Ulm, Germany|Research Site, Amsterdam, Netherlands|Research Site, Kraków, Poland|Research Site, Skórzewo, Poland|Research Site, Cardiff, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Southampton, United Kingdom|Research Site, Sutton, United Kingdom	https://ClinicalTrials.gov/show/NCT03263637
177	Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant	Recruiting	No Results Available	HIV Infection|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Plasmablastic Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Non-Hodgkin Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Follicular Lymphoma|Stage III Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Follicular Lymphoma|Stage IV Mantle Cell Lymphoma	Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Drug: Cytarabine|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Biological: Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells|Drug: Melphalan|Procedure: Peripheral Blood Stem Cell Transplantation	UC San Diego Moores Cancer Center, La Jolla, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT02797470
178	Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies	Recruiting	No Results Available	Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia in Remission|Hematopoietic Cell Transplantation Recipient|JAK2 Gene Mutation|Loss of Chromosome 17p|Mantle Cell Lymphoma|Minimal Residual Disease|Myelodysplastic Syndrome|Non-Hodgkin Lymphoma|Plasma Cell Myeloma|RAS Family Gene Mutation|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Hematologic Malignancy|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Therapy-Related Acute Myeloid Leukemia|Therapy-Related Myelodysplastic Syndrome|TP53 Gene Mutation	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Biological: Irradiated Allogeneic Cells	Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States	https://ClinicalTrials.gov/show/NCT03272633
179	Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma	Recruiting	No Results Available	Aggressive Non-Hodgkin Lymphoma|Indolent Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma	Procedure: Cryosurgery|Biological: Dendritic Cell Therapy|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Biological: Pneumococcal 13-valent Conjugate Vaccine|Other: Quality-of-Life Assessment	Mayo Clinic in Rochester, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT03035331
180	Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer	Recruiting	No Results Available	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Leukemia in Remission|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia With FLT3/ITD Mutation|Acute Myeloid Leukemia With Gene Mutations|Aplastic Anemia|B-Cell Non-Hodgkin Lymphoma|CD40 Ligand Deficiency|Chronic Granulomatous Disease|Chronic Leukemia in Remission|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Congenital Amegakaryocytic Thrombocytopenia|Congenital Neutropenia|Congenital Pure Red Cell Aplasia|Glanzmann Thrombasthenia|Immunodeficiency Syndrome|Myelodysplastic Syndrome|Myelofibrosis|Myeloproliferative Neoplasm|Paroxysmal Nocturnal Hemoglobinuria|Plasma Cell Myeloma|Polycythemia Vera|Recurrent Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndrome|Severe Aplastic Anemia|Shwachman-Diamond Syndrome|Sickle Cell Disease|T-Cell Non-Hodgkin Lymphoma|Thalassemia|Waldenstrom Macroglobulinemia|Wiskott-Aldrich Syndrome	Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Procedure: Peripheral Blood Stem Cell Transplantation|Radiation: Total-Body Irradiation	Roswell Park Cancer Institute, Buffalo, New York, United States	https://ClinicalTrials.gov/show/NCT03333486
181	PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies	Recruiting	No Results Available	Stage IV Gastric Carcinoma|Stage IV Nasopharyngeal Carcinoma|T-Cell Lymphoma Stage IV|Stage IV Adult Hodgkin Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma	Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Interleukin-2	The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China|The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT03044743
182	DS-3201b in Participants With Lymphomas	Recruiting	No Results Available	Lymphoma, Malignant|Non-hodgkin Lymphoma	Drug: DS-3201b	City of Hope National Medical center, Duarte, California, United States|Yale University, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Medicine, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Nagoya City University Hospital, Nagoya-shi, Aichi, Japan|National Cancer Center Hospital East, Kahiwa-shi, Chiba, Japan|Iwate Medical University Hospital, Morioka-shi, Iwate, Japan|Imamura General Hospital, Kagoshima-shi, Kagoshima, Japan|Kagoshima University Hospital, Kagoshima-shi, Kagoshima, Japan|Kumamoto University Hosipital, Kumamoto-shi, Kumamoto, Japan|Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan|University of the Ryukyus Hospital, Nakagami-gun, Okinawa, Japan|The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan|National Cancer Center Hospital, Chuo Ku, Toyko, Japan	https://ClinicalTrials.gov/show/NCT02732275
183	Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies	Recruiting	No Results Available	Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Biphenotypic Acute Leukemia|Undifferentiated Leukemia|Prolymphocytic Leukemia|Myelodysplastic Syndromes|Chronic Myelogenous Leukemia|Myeloproliferative Neoplasm|Relapsed Large Cell Lymphoma|Mantle Cell Lymphoma|Hodgkin Lymphoma|Burkitt Lymphoma|Relapsed T-Cell Lymphoma|Relapsed Chronic Lymphocytic Leukemia|Relapsed Small Lymphocytic Lymphoma|Relapsed Marginal B-cell Lymphoma|Relapsed Follicular Lymphoma|Lymphoplasmacytic Lymphoma	Drug: Fludarabine|Drug: Melphalan|Radiation: Total Body Irradiation	H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States	https://ClinicalTrials.gov/show/NCT04191187
184	UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep	Recruiting	No Results Available	Acute Leukemia|Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia/Lymphoma|Burkitt's Lymphoma|Natural Killer Cell Malignancies|Chronic Myelogenous Leukemia|Myelodysplastic Syndrome|Large-cell Lymphoma|Hodgkin Lymphoma|Multiple Myeloma|Relapsed Chronic Lymphocytic Leukemia|Relapsed Small Lymphocytic Lymphoma|Marginal Zone B-cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle-cell Lymphoma|Prolymphocytic Leukemia|Bone Marrow Failure Syndromes|Myeloproliferative Neoplasms/Myelofibrosis|Biphenotypic/Undifferentiated/Prolymphocytic Leukemias|MRD Positive Leukemia|Leukemia or MDS in Aplasia|Relapsed T-Cell Lymphoma|Relapsed Multiple Myeloma|Plasma Cell Leukemia	Drug: Fludarabine|Drug: Cyclophosphamide|Drug: MMF|Drug: Sirolimus|Radiation: TBI|Biological: Umbilical cord blood cell infusion|Biological: ATG	Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States	https://ClinicalTrials.gov/show/NCT02722668
185	Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides	Recruiting	No Results Available	Localized Skin Lesion|Mycosis Fungoides	Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Radiation: Radiation Therapy	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT03398161
186	Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome	Recruiting	No Results Available	Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8	Drug: Duvelisib|Biological: Nivolumab	Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States	https://ClinicalTrials.gov/show/NCT04652960
187	Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome	Recruiting	No Results Available	Sezary Syndrome|Mycosis Fungoides	Drug: Mogamulizumab|Radiation: LD TSEBT	Stanford Cancer Center, Stanford, California, United States	https://ClinicalTrials.gov/show/NCT04256018
188	Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides	Recruiting	No Results Available	Mycosis Fungoides|Sezary Syndrome|Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8	Biological: Pembrolizumab	Mayo Clinic in Florida, Jacksonville, Florida, United States	https://ClinicalTrials.gov/show/NCT03695471
189	Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients	Recruiting	No Results Available	Mycosis Fungoides|Lymphomatoid Papulosis|Sezary Syndrome	Drug: brentuximab vedotin	Stanford University Medical Center, Stanford, California, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States	https://ClinicalTrials.gov/show/NCT03587844
190	ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors	Recruiting	No Results Available	Lymphoblastic Lymphoma	Drug: Anti-human Thymoglobulin|Drug: Placebo	Shanghai First People's HOSPITAL, Shanghai, Shanghai, China|Shanghai First People's HOSPITAL, Shanghai, China	https://ClinicalTrials.gov/show/NCT02938741
191	A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)	Recruiting	No Results Available	Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)	Drug: TQ-B3101 capsule	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04306887
192	CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas	Recruiting	No Results Available	Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma	Biological: ICAR30 T cells	Weifang People's Hospital, Weifang, Shandong, China	https://ClinicalTrials.gov/show/NCT03383965
193	A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma	Recruiting	No Results Available	Anaplastic Large Cell Lymphoma, ALK-Positive	Drug: Lorlatinib	Asst-Monza, Monza, Italy/MB, Italy	https://ClinicalTrials.gov/show/NCT03505554
194	Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)	Recruiting	No Results Available	Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma	Drug: Nivolumab cohort 1|Drug: Nivolumab cohort 2	Gustave Roussy, Villejuif, Val De Marne, France	https://ClinicalTrials.gov/show/NCT03703050
195	Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL	Recruiting	No Results Available	Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Follicular Lymphoma Grade IIIb|Transformed Lymphoma|EBV-Positive DLBCL, Nos|ALK-Positive Anaplastic Large Cell Lymphoma	Drug: Camrelizumab|Drug: Apatinib	Department of Medical Oncology, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04476459
196	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies	Recruiting	No Results Available	Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Adult Diffuse Large Cell Lymphoma|Anaplastic Large Cell Lymphoma|Burkitt Lymphoma|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Hodgkin Lymphoma|Lymphoblastic Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndrome|Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Follicular Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Small Lymphocytic Lymphoma	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclophosphamide|Drug: Cyclosporine|Biological: Filgrastim|Drug: Fludarabine|Drug: Mycophenolate Mofetil|Drug: Mycophenolate Sodium|Radiation: Total-Body Irradiation|Drug: Treosulfan	Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT04195633
197	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)	Recruiting	No Results Available	Breast Cancer|Cholangiocarcinoma|Colorectal Cancer|Head and Neck Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neuroendocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Primary Brain Tumors|Renal Cell Carcinoma|Sarcomas|Salivary Gland Cancers|Adult Solid Tumor	Drug: Entrectinib	Western Regional Medical Center at Cancer Treatment Centers of America, Goodyear, Arizona, United States|Dignity Health St Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|City of Hope Cancer Center; Division of Medical Oncology & Experimental Therapeutics, Duarte, California, United States|Scripps Clinic, La Jolla, California, United States|University of California San Diego Moores Cancer Center; Dept of Lung Cancer, La Jolla, California, United States|University of Southern California Medical Center, Los Angeles, California, United States|Univ Of California Irvine College Of Medicine; 300194620, Orange, California, United States|Southern California Kaiser Permanente, San Diego, California, United States|UCSF Mount Zion Medical Ctr, San Francisco, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Georgetown University Medical Center Lombardi Cancer Center, Washington, District of Columbia, United States|Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States|H. Lee Moffitt Cancer Center and Research Inst., Tampa, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|University Cancer & Blood Center, LLC; Research, Athens, Georgia, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Southeastern Regional Medical Center, Inc., Newnan, Georgia, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Northwestern University, Chicago, Illinois, United States|Advocate Medical Group - Park Ridge, Luther Lane - Oncology, Park Ridge, Illinois, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|Weinberg Cancer Institution at Franklin Square, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Regents of the University of Minnesota, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|North Shore Hem Onc Associates, East Setauket, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke Cancer Institute, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|OSU, James Cancer Hospital, Columbus, Ohio, United States|Cancer Treatment Centers of America; Tulsa, Tulsa, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health & Science Univ, Portland, Oregon, United States|Cancer Treatment Centers of America - Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|University Hospital Medical Oncology Clinic; Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Baylor Scott & White Health, Temple, Texas, United States|University of Utah Hospitals & Clinics, Salt Lake City, Utah, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Oncology Associates - Hampton, Hampton, Virginia, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States|Wheaton Franciscan Cancer Care-All Saints, Franklin, Wisconsin, United States|Border Medical Oncology Research Unit, Albury, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Newcastle Private Hospital, New Lambton Heights, New South Wales, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Antwerp University Hospital, Edegem, Belgium|Beijing Cancer Hospital, Beijing, China|Beijing Union Hospital, Beijing, China|Hunan Cancer Hospital, Changsha City, China|Sichuan Provincial Cancer Hospital, Chengdu, China|Fujian Provincial Cancer Hospital, Fuzhou City, China|Cancer Center of Guangzhou Medical University, Guangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Fudan University Shanghai Cancer Center, Shanghai City, China|Shanghai chest hospital, Shanghai, China|Shenzhen People's Hospital, Shenzhen, China|Tianjin Cancer Hospital, Tianjin, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China|Zhejiang Cancer Hospital, Zhejiang, China|Institut de Cancerologie de l Ouest, Angers, France|Institut Bergonie; Oncologie, Bordeaux, France|Centre Oscar Lambret; Chir Cancerologie General, Lille, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Hôpital de la Timone; Oncologie Médicale Hématologie & Soins Palliatifs, Marseille cedex 5, France|Hôpital Nord - AP-HM Marseille#; Service d'Oncologie Multidisciplinaire, Marseille, France|Institut de Recherche en Cancérologie de Montpellier, Montpellier cedex 5, France|Hôpital Européen Georges Pompidou; Hématologie Oncologie, Paris cedex 15, France|Institut Curie; Oncologie Medicale, Paris, France|Institut De Cancerologie De L'ouest - Rene Gauducheau - Biology, Saint Herblain, France|Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, France|Institut Gustave Roussy; Pathologie Thoracique, Villejuif cedex, France|Charite Universitaetsmedizin Berlin - Campus Charite Mitte ; Charite Comprehensive Cancer Center, Berlin, Germany|Evang. Lungenklinik Berlin Klinik für Pneumologie, Berlin, Germany|Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Germany|Asklepios-Fachkliniken Muenchen-Gauting; Onkologie, Gauting, Germany|Universitaetsmedizin Goettingen; Abteilung Haematologie und Onkologie, Göttingen, Germany|NCT Uniklinikum Heidelberg; Medizinische Onkologie, Heidelberg, Germany|Universitaetsklinikum Koeln; Innere Medizin I, Haematologie, Köln, Germany|Hong Kong Integrated Oncology Centre, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|The University of Hong Kong, Hong Kong, Hong Kong|Queen Elizabeth Hospital, Kowloon, Hong Kong|The Chinese University of Hong Kong, Shatin, Hong Kong|Seconda Università degli Studi di Napoli; Servizio Epato-Gastroenterologia, Napoli, Campania, Italy|Università Campus Bio-Medico di Roma; Oncologia Medica, Roma, Lazio, Italy|Azienda Ospedaliero Universitaria San Martino; Lung Cancer Unit, Genova, Liguria, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda); Oncologico -Onc.Falck, Milano, Lombardia, Italy|Fondazione del Piemonte per l'Oncologia - IRCCS;Ematologia, Candiolo, Piemonte, Italy|Azienda Ospedaliero-Universitaria S.Luigi Gonzaga; SSD Oncologia Polmonare, Orbassano, Piemonte, Italy|A.O Città della Salute e della Scienza di Torino; Colorectal Cancer Unit (CRCU) - SSCVD, Torino, Piemonte, Italy|Azienda Ospedaliero - Universitaria Pisana U.O. Oncologia Medica 2 Universitaria - Polo Oncologico, Pisa, Toscana, Italy|Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia ; S.C. Oncologia Medica, Perugia, Umbria, Italy|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto, Italy|Aichi Cancer Center Hospital; Respiratory Medicine, Aichi, Japan|NHO Shikoku Cancer Center; Dept of Respiratory Medicine, Ehime, Japan|NHO Kyushu Cancer Center, Fukuoka, Japan|Hyogo Cancer Center, Dept of Respiratory Medicine, Hyogo, Japan|National Cancer Center Hospital; Dept of Respiratory Medicine, Kashiwa-shi, Japan|Miyagi Cancer Center; Respiratory Medicine, Miyagi, Japan|Niigata Cancer Center Hospital; Internal Medicine, Niigata, Japan|OSAKA CITY GENERAL HOSPITAL;Medical Oncology, Osaka, Japan|Kindai University Hospital; Medical Oncology, Osaka, Japan|Shizuoka Cancer Center; Respiratory Internal Medicine, Shizuoka, Japan|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center., Seoul, Korea, Republic of|NKI The Netherlands Cancer Institute, Amsterdam, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdańsk, Poland|Centrum Onkologii-Instytut im.M.Sklodowskiej Curie; Dept of Nuclear Med. and Endocrine Oncology, Gliwice, Poland|Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy; Dept of Pulmonology & subdiv. of oncology, Otwock, Poland|Szpital Kliniczny Przemienienia Panskiego Uni. Medycznego im. Karola Marcinkowskiego; Chemotherapy, Poznań, Poland|Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland|National University Hospital; Haematology/Oncology, Singapore, Singapore|National Cancer Centre, Singapore, Singapore|Centro Nacional de Investigaciones Oncológicas(CNIO); Gastrointestinal Cancer Clinical Research Unit, Fuenlabrada, Madrid, Spain|Hospital Universitari Vall dHebron; Oncology, Barcelona, Spain|Hospital Universitario de La Princesa; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Ramon y Cajal; Servicio de Farmacia, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|START Madrid. Centro Integral Oncologico Clara Campal; Unidad de Fase I-Oncologica, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Changhua Christian Hospital, Chang Hua, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital, Cambridge, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom	https://ClinicalTrials.gov/show/NCT02568267
198	Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Recruiting	No Results Available	Acute Biphenotypic Leukemia|Acute Erythroid Leukemia in Remission|Acute Leukemia in Remission|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Acute Myeloid Leukemia in Remission|Acute Myeloid Leukemia With FLT3/ITD Mutation|Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM|Acute Myeloid Leukemia With Multilineage Dysplasia|Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Complete Remission|B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Burkitt Lymphoma|Childhood Acute Lymphoblastic Leukemia in Complete Remission|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|Myelodysplastic Syndrome|Recurrent Anaplastic Large Cell Lymphoma|Blasts Under 5 Percent of Bone Marrow Nucleated Cells|Recurrent Follicular Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma|Secondary Acute Myeloid Leukemia|T Lymphoblastic Lymphoma|Hematopoietic Cell Transplant Recipient	Drug: Cyclophosphamide|Biological: Filgrastim|Drug: Fludarabine Phosphate|Procedure: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Tacrolimus|Radiation: Total-Body Irradiation|Drug: Fludarabine	VA Puget Sound Health Care System, Seattle, Washington, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT01028716
199	Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma	Recruiting	No Results Available	SenL-T7 CAR T Cells CD7+ Lymphoma	Biological: Senl-T7	Hebei yanda Ludaopei Hospital, Yanda, Hebei, China	https://ClinicalTrials.gov/show/NCT04928105
200	Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma	Recruiting	No Results Available	Adult T-cell Leukemia-Lymphoma|ATLL	Drug: Belinostat|Drug: Zidovudine|Drug: Interferon-Alfa-2b|Drug: Pegylated Interferon-Alfa-2b	University of Miami, Miami, Florida, United States	https://ClinicalTrials.gov/show/NCT02737046
201	A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH	Recruiting	No Results Available	Isocitrate Dehydrogenase Gene Mutation	Drug: HMPL-306	Emory University, Atlanta, Georgia, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT04764474
202	3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer	Recruiting	No Results Available	Brain and Central Nervous System Tumors|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Unspecified Adult Solid Tumor, Protocol Specific	Device: 3'-deoxy-3'-[18F]fluorothymidine	Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States	https://ClinicalTrials.gov/show/NCT00935090
203	BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma	Recruiting	No Results Available	Lymphoma|Adult T-Cell Leukemia/Lymphoma|Lymphatic Diseases	Drug: Brentuximab Vedotin|Drug: CHEP	Boston Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States|Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States	https://ClinicalTrials.gov/show/NCT03264131
204	A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors	Recruiting	No Results Available	Hematologic Malignancies|Solid Tumor	Drug: TTI-621|Drug: TTI-621 plus Rituximab|Drug: TTI-621 plus Nivolumab	City of Hope National Medical Center, Duarte, California, United States|Stanford Cancer Institute, Palo Alto, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Mayo Clinic, Jacksonville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States|Hackensack Meridian Health John Theurer Cancer Center, Hackensack, New Jersey, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States|Columbia Univeristy, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Oregon Health and Sciences University, Portland, Oregon, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|Princess Margaret Cancer Center, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT02663518
205	Toripalimab in Combination With R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma	Recruiting	No Results Available	Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Follicular Lymphoma Grade IIIb|Transformed Lymphoma|EBV-Positive DLBCL, Nos|ALK-Positive Anaplastic Large Cell Lymphoma	Drug: Toripalimab|Drug: R-CHOP Protocol	Department of hematology department, Nanfang hospital, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04058470
206	Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL)	Recruiting	No Results Available	Acute Adult T-Cell Leukemia/Lymphoma|Adult T-Cell Leukemia/Lymphoma|Chronic Adult T-Cell Leukemia/Lymphoma|HTLV-1 Infection	Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Drug: Lenalidomide|Drug: Prednisone|Drug: Vincristine Sulfate	Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States	https://ClinicalTrials.gov/show/NCT04301076
207	Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL	Recruiting	No Results Available	Non-GCB/ABC Diffuse Large B-Cell Lymphoma|High-grade B-cell Lymphoma|Follicular Lymphoma Grade IIIb|Transformed Lymphoma|EBV-Positive DLBCL, Nos|ALK-Positive Anaplastic Large Cell Lymphoma	Drug: PD-1 Antibody|Drug: Lenalidomide	Department of Medical Oncology, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04796857
208	CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL	Recruiting	No Results Available	Pediatric Anaplastic Large Cell Lymphoma	Drug: P regimen|Drug: Course A1 + Vin|Drug: Course B1 +Vin|Drug: Course A2 + Vin|Drug: Course B2 +Vin|Drug: Course A3 + Vin|Drug: Course B3 +Vin|Drug: Maintenance therapy	Shanghai Children's Medical Center, Shanghai, China	https://ClinicalTrials.gov/show/NCT04881838
209	Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors	Not yet recruiting	No Results Available	Anaplastic Large Cell Lymphoma, ALK-Positive|Inflammatory Myofibroblastic Tumor|Other Solid Tumor	Drug: Brigatinib		https://ClinicalTrials.gov/show/NCT04925609
210	Vinorelbine for Recurrent ALCL-2017	Recruiting	No Results Available	Anaplastic Large Cell Lymphoma|Vinorelbine	Drug: Vinorelbine	Shanghai Children's Medical Center, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT03443128
211	Dual Target CAR-T Cells in B-cell Lymphoma	Recruiting	No Results Available	Lymphoma, B-Cell|Relapse/Recurrence|Refractory Lymphoma|Dual-target CAR-T Cells	Biological: dual target CAR-T cell therapy	Shenzhen University General hospital, Shenzhen, Guangdong, China	https://ClinicalTrials.gov/show/NCT04723914
212	The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma	Recruiting	No Results Available	Relapsed and Refractory B Cell Lymphoma|Non-Hodgkin Lymphoma	Biological: CD20 CAR-T	The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT04169932
213	Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Leukemia or T-cell Lymphoblastic Lymphoma	Recruiting	No Results Available	SenL-T7 CAR T Cells for CD7+ Leukemia or T-LBL	Biological: Senl-T7	Hebei yanda Ludaopei Hospital, Beijing, Hebei, China	https://ClinicalTrials.gov/show/NCT04916860
214	Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL	Recruiting	No Results Available	Relapase and Refractory B-cell Non-Hodgkin's Lymphoma|Decitabine-primed Tandem CD19/CD20 CAR T Cells	Biological: Decitabine-primed Tandem CAR19/20 engineered T cells	Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04697940
215	CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)	Recruiting	No Results Available	Hodgkin's Lymphoma|Non-Hodgkin Lymphoma	Genetic: CAR T Cells|Drug: Cyclophosphamide|Drug: Fludarabine	Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT02917083
216	Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma	Not yet recruiting	No Results Available	Lymphoma	Biological: Anti-CD19-CAR		https://ClinicalTrials.gov/show/NCT04100187
217	CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma	Recruiting	No Results Available	Mantle Cell Lymphoma	Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells	Peking University Cancer Hospital, Beijing, Beijing, China|Peking University Third Hospital, Beijing, Beijing, China|Fujian Medical University Consonancy Hospital, Fuzhou, Fujiang, China|Guangdong Province people hospital, Guanzhou, Guangdong, China|Henan Province Cancer Hospital, Zhengzhou, Henan, China|Jiangsu Province People Hospital, Nanjing, Jiangsu, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, China|Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China|Tianjin Cancer Hospital, Tianjin, Tianjin, China|The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China|Zhejiang province Cancer Hospital, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04718883
218	Multi-CAR-T Cells Targeting B Cell Lymphomas	Recruiting	No Results Available	B Cell Lymphoma (BCL)	Biological: 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2	Shenzhen Children's Hospital, Shenzhen, Guangdong, China|Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China|The Seventh Affilliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China	https://ClinicalTrials.gov/show/NCT04429438
219	Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)	Recruiting	No Results Available	Non Hodgkin Lymphoma	Biological: UCD19 CAR T Cells	University of Colorado Hospital, Aurora, Colorado, United States	https://ClinicalTrials.gov/show/NCT04240808
220	Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma	Recruiting	No Results Available	Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma	Biological: TAA-T cells|Drug: Nivolumab	Children's National Medical Center, Washington, District of Columbia, United States|Utah University School of Medicine/Huntsman Cancer Institute, Salt Lake City, Utah, United States	https://ClinicalTrials.gov/show/NCT03843294
221	Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma	Not yet recruiting	No Results Available	Lymphoma, B-Cell	Biological: TAC01-CD19		https://ClinicalTrials.gov/show/NCT03880279
222	Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma	Recruiting	No Results Available	Relapsed Hodgkin Lymphoma|Refractory Hodgkin Lymphoma	Biological: Nivolumab|Biological: Pembrolizumab	Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States	https://ClinicalTrials.gov/show/NCT04134325
223	CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma	Recruiting	No Results Available	Lymphoma, Non-Hodgkin|Diffuse Large B Cell Lymphoma|Follicular Lymphoma	Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells	Beijing Cancer Hospital, Beijing, Beijing, China|Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China|Beijing Hospital, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China|Guangdong General Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital of Zhenzhou Universtity, Zhenzhou, Henan, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, China|Shanghai East Hospital, Shanghai, Shanghai, China|Institute of Hematology&Hospital of Blood Disease CAMS, Tianjin, Tianjin, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04089215
224	Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma	Recruiting	No Results Available	Lymphoma, B-Cell	Biological: CD19-CD22 CAR-T cells	Hematology Department of ShanXi Cancer Hospital, Taiyuan, Shanxi, China	https://ClinicalTrials.gov/show/NCT04715217
225	Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma	Recruiting	No Results Available	Primary CNS Lymphoma	Biological: CD19CAR T-cells	University College London Hospital, London, United Kingdom	https://ClinicalTrials.gov/show/NCT04443829
226	Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma	Recruiting	No Results Available	Non-hodgkin's Lymphoma	Biological: CD19 CAR-T	BeiJing Ludaopei Hospital, Beijing, Yizhuang, China|He bei Yan da Lu dao pei Hospital, Yanda, China	https://ClinicalTrials.gov/show/NCT04447547
227	Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma	Not yet recruiting	No Results Available	Lymphoma, B Cell	Biological: IL-2 pre-treated CD19 cells|Biological: IL-7/IL-15 pre-treated CD19 cells	First People's Hospital of Changzhou, Changzhou, Jiangsu, China	https://ClinicalTrials.gov/show/NCT02992834
228	Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Recruiting	No Results Available	Recurrent Mantle Cell Lymphoma|Refractory Mantle Cell Lymphoma	Drug: Acalabrutinib|Biological: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes	City of Hope Comprehensive Cancer Center, Duarte, California, United States	https://ClinicalTrials.gov/show/NCT04484012
229	CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma	Recruiting	No Results Available	Diffuse Large B Cell Lymphoma	Biological: JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)	Ruijin hospital, Shanghai, Shanghai, China|Zhejiang university school of medicine first affiliated hospital, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04812691
230	Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA-2)	Recruiting	No Results Available	Relapsed/Refractory Large B Cell Lymphoma	Genetic: ALLO-501A|Biological: ALLO-647|Drug: Fludarabine|Drug: Cyclophosphamide	City of Hope, Duarte, California, United States|UCLA Medical Center, Los Angeles, California, United States|Stanford Cancer Institute, Palo Alto, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|University of Miami, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Harvard Massachusetts General Hospital, Boston, Massachusetts, United States|Montefiore Einstein Center for Cancer Care, Bronx, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|St. David's South Austin Medical Center, Austin, Texas, United States|MD Anderson Cancer Center - University of Texas, Houston, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT04416984
231	Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas	Recruiting	No Results Available	Acute Lymphoblastic Leukemia ,Lymphomas	Biological: Anti-CD19 CAR-T	The First Affiliated Hospital of Nangchang University, Nanchang, Jiangxi, China	https://ClinicalTrials.gov/show/NCT04196205
232	Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study	Not yet recruiting	No Results Available	Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma	Drug: Duvelisib|Biological: Tisagenlecleucel	Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT04890236
233	Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma	Recruiting	No Results Available	Relapsed/Refractory Large B Cell Lymphoma|Relapsed/Refractory Follicular Lymphoma	Genetic: ALLO-501|Biological: ALLO-647|Drug: Fludarabine|Drug: Cyclophosphamide	Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|University of California, Los Angeles, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Moffitt Cancer Center, Tampa, Florida, United States|Norton Cancer Institute, Louisville, Kentucky, United States|St. Davids South Austin Medical Center, Austin, Texas, United States|MD Anderson, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT03939026
234	Auto Stem Cell Transplant for Lymphoma Patients	Recruiting	No Results Available	Non-Hodgkin Lymphoma|Hodgkin Lymphoma	Drug: Etoposide|Drug: BCNU|Drug: AraC|Drug: Melphalan|Procedure: Peripheral blood stem cell transplantation|Biological: G-CSF|Drug: Cyclophosphamide|Radiation: Total Body Irradiation	Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States	https://ClinicalTrials.gov/show/NCT03125642
235	A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma	Recruiting	No Results Available	Leukemia|Lymphoma	Biological: Chimeric Antigen Receptor Modified T cells Targeting CD19	Southwest Hospital of Third Millitary Medical University, Chongqing, Chongqing, China	https://ClinicalTrials.gov/show/NCT02349698
236	Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy	Not yet recruiting	No Results Available	B-Cell Non-Hodgkin Lymphoma	Biological: Anakinra|Biological: Axicabtagene Ciloleucel	Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT04359784
237	A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	Recruiting	No Results Available	Lymphoma Non-Hodgkin|Agressive Lymphoma|Diffuse-large B-cell Lymphoma (DLBCL)	Biological: CC-97540	University of Alabama, Birmingham, Alabama, United States|Northside Hospital - Blood and Bone Marrow Transplant Group of Georgia, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Oregon Health & Science University (OHSU), Portland, Oregon, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States	https://ClinicalTrials.gov/show/NCT04231747
238	Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy	Recruiting	No Results Available	Diffuse Large B-Cell Lymphoma Refractory|Refractory Indolent Adult Non-Hodgkin Lymphoma|Refractory Transformed B-cell Non-Hodgkin Lymphoma|Refractory Primary Mediastinal Large B-Cell Cell Lymphoma|Refractory Mantle Cell Lymphoma	Drug: Obinutuzumab|Drug: RO7082859	CHU de Clermont Ferrand, Clermont Ferrand, France|Hopital Henri Mondor, Créteil, France|CHU de Dijon - Hôpital le Bocage, Dijon, France|CHRU Lille - Hôpital Claude Huriez, Lille, France|CHU Montpellier, Montpellier, France|CHU Nantes, Nantes, France|Hôpital Saint Louis, Paris, France|APHP - Hôpital de la Pitiè Salpetrière, Paris, France|APHP - Hôpital Saint Antoine, Paris, France|CHU de Bordeaux - Hôpital Haut Leveque, Pessac, France|CHU Lyon Sud, Pierre Bénite, France|CHU de Rennes - Hôpital Pontchaillou, Rennes, France|Centre Henri Becquerel, Rouen, France|IUCT Oncopole, Toulouse, France|CHU de Brabois, Vandoeuvre les Nancy, France	https://ClinicalTrials.gov/show/NCT04703686
239	Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.	Recruiting	No Results Available	CD19-positive|Diffuse Large B-cell Lymphoma|Follicular Lymphoma	Drug: Human CD19 targeted T Cells Injection	The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|Fudan University Zhongshan Hospital, Shanghai, Shanghai, China|The First Affilicated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT03720457
240	CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma	Recruiting	No Results Available	B-Cell Lymphoma Stage I|Refractory|Relapsed	Biological: CD19/CD20 bispecific CAR-T cells	Cancer Hospital Affiliate to Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China|Henan Cancer Hospital, Zhengzhou, Henan, China	https://ClinicalTrials.gov/show/NCT03881761
241	CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma	Not yet recruiting	No Results Available	Acute Lymphoblastic Leukemia|Burkitt Lymphoma	Biological: CD19 CAR and PD-1 knock out engineered T-cells|Biological: CD19 CAR T-cells		https://ClinicalTrials.gov/show/NCT03298828
242	ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma	Recruiting	No Results Available	Leukemia|Lymphoma	Drug: ET019003-T Cells	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT04014894
243	CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma	Recruiting	No Results Available	Diffuse Large B Cell Lymphoma|Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|DLBCL	Biological: AUTO3	City of Hope Hospital, Duarte, California, United States|Colorado Blood Cancer Institute at Presbyterian/St. Luke's Medical Center/Sarah Cannon Research Institute, Denver, Colorado, United States|Sylvester Comprehensive Cancer Center / University of Miami, Miami, Florida, United States|Siteman Cancer Center / Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|TriStar Centennial Medical Center /Sarah Cannon Research Institute, Nashville, Tennessee, United States|St David's South Austin Medical Center /Sarah Cannon Research Institute, Austin, Texas, United States|The Beatson West of Scotland Cancer Centre / Queen Elizabeth University Hospital, Glasgow, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom	https://ClinicalTrials.gov/show/NCT03287817
244	Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia	Recruiting	No Results Available	Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia	Biological: Blinatumomab Expanded T-cells (BET)	ASST - Papa Giovanni XXIII, Bergamo, Italy	https://ClinicalTrials.gov/show/NCT03823365
245	Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT	Recruiting	No Results Available	Hematologic Malignancies	Biological: Haplo HCT <55 years old|Biological: Haplo HCT ≥55 years old|Drug: GVHD Prophylaxis|Biological: Haplo HCT ≥55 and < 65 years old|Biological: Haplo HCT ≥65 and ≤75 years old	Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States	https://ClinicalTrials.gov/show/NCT02988466
246	Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma	Recruiting	No Results Available	Refractory Non-Hodgkin Lymphoma|Burkitt Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Diffuse Large B Cell Lymphoma|Small Lymphocytic Lymphoma|Transformed Lymphoma	Drug: Fludarabine|Drug: Cyclophosphamide|Biological: anti-CD19 CAR-T cells	University of California, San Francisco, San Francisco, California, United States	https://ClinicalTrials.gov/show/NCT04545762
247	Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells	Not yet recruiting	No Results Available	T-cell Acute Lymphoblastic Leukemia|T-cell Acute Lymphoblastic Lymphoma|T-non-Hodgkin Lymphoma	Genetic: CD7.CAR/28zeta CAR T cells|Drug: Fludarabine|Drug: Cytoxan	Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT03690011
248	CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia	Recruiting	No Results Available	B Cell Lymphoma|B-cell Acute Lymphoblastic Leukemia	Biological: Anti-CD19 CAR-T Cells Injection	Kunming Yan'an Hospital, Oncology Department, Kunming, Yunnan, China	https://ClinicalTrials.gov/show/NCT03854994
249	Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma	Recruiting	No Results Available	B-Cell Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	Drug: Acalabrutinib|Biological: Axicabtagene Ciloleucel	Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT04257578
250	Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL	Not yet recruiting	No Results Available	Leukemia|Lymphoma	Biological: :Anti-CD22-CAR		https://ClinicalTrials.gov/show/NCT04163575
251	Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia	Recruiting	No Results Available	B Cell Lymphoma|B-cell Acute Lymphoblastic Leukemia	Biological: Anti-CD19 CAR-T Cells Injection	Kunming Yan'an Hospital, Kunming, Yunnan, China	https://ClinicalTrials.gov/show/NCT04289220
252	Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL	Not yet recruiting	No Results Available	Leukemia|Lymphoma	Biological: Anti-CD19-CAR	Beijing Cancer Hospital, Beijing, Beijing, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|Hebei Yanda Ludaopei Hospital, Sanhe, Hebei, China|First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Huai'An First People'S Hospital, Huaian, Jiangsu, China|Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China|First Hospital of Jilin University, Changchun, Jilin, China|Shanxi Dayi Hospital, Taiyuan, Shanxi, China|Tianjin people's hospital, Tianjin, Tianjin, China|Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China|Beijing DOING Biomedical Co., Ltd, Beijing, China	https://ClinicalTrials.gov/show/NCT02546739
253	Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma	Recruiting	No Results Available	Lymphoma|Lymphoma, B-Cell|Immune System Diseases|Immunoproliferative Disorders|Lymphatic Diseases	Biological: iC9-CAR19 T cells|Drug: Bendamustine|Drug: Fludarabine|Drug: AP1903|Drug: Cyclophosphamide	Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States	https://ClinicalTrials.gov/show/NCT03696784
254	Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)	Recruiting	No Results Available	Hodgkin Lymphoma, Adult|Hodgkin Disease Recurrent|Hodgkin Disease Refractory|Hodgkin Disease, Pediatric	Drug: CD30.CAR-T|Drug: Fludarabine|Drug: Bendamustine	City of Hope Comprehensive Cancer Center, Duarte, California, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT04268706
255	Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen	Recruiting	No Results Available	T-cell Acute Lymphoblastic Lymphoma|T-non-Hodgkin Lymphoma|T-cell Acute Lymphoblastic Leukemia	Genetic: Autologous CD5.CAR/28zeta CAR T cells|Drug: Fludarabine|Drug: Cytoxan|Genetic: Allogeneic CD5.CAR/28zeta CAR T cells	Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT03081910
256	Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL	Not yet recruiting	No Results Available	Leukemia|Lymphoma	Biological: anti-CD19 anti-CD20 Bispecific CAR-T	Hebei Yanda Ludaopei Hospital, Sanhe, Hebei, China	https://ClinicalTrials.gov/show/NCT03271515
257	Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19	Recruiting	No Results Available	Leukemia, Lymphoblastic, Acute, Lymphoma	Biological: CD19CAT-41BBZ CAR T-cells	University College London Hospital, London, United Kingdom	https://ClinicalTrials.gov/show/NCT02935257
258	A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma	Recruiting	No Results Available	B Cell Leukemia|B Cell Lymphoma	Biological: Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells	Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03398967
259	CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma	Recruiting	No Results Available	Leukemia|Lymphoma, Large B-Cell, Diffuse|Leukemia, B-cell|Lymphoma, B-Cell|Leukemia, Lymphocytic, Chronic, B-Cell	Biological: CD19 CAR-T cells	920th Hospital of Joint Logistics Support Force, Kunming, Yunnan, China	https://ClinicalTrials.gov/show/NCT04271410
260	CAR-T Cells in Treating Patients With Relapsed or Refractory NHL	Recruiting	No Results Available	Refractory Indolent Adult Non-Hodgkin Lymphoma	Drug: CD19 CAR-T|Drug: CD22 CAR-T|Drug: CD19+CD22 CAR-T|Drug: Fludarabine|Drug: Cyclophosphamide	No.2 Hospital of Hebei Medical University, Shijiazhuang, Hebei, China	https://ClinicalTrials.gov/show/NCT04626739
261	Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)	Recruiting	No Results Available	Relapsed Non Hodgkin Lymphoma|Relapsed Adult ALL|Relapsed Pediatric ALL	Biological: autologous CD19-directed chimeric antigen receptor (CAR) T-cells	Foothills Medical Centre, Calgary, Alberta, Canada|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Alberta Children's Hospital, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Stollery Children's Hospital, Edmonton, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada	https://ClinicalTrials.gov/show/NCT03938987
262	A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies	Recruiting	No Results Available	Acute Lymphoblastic Leukemia|Non-Hodgkin's Lymphoma	Drug: CAR-T cells|Procedure: Ommaya Reservoir	The First Affiliated Hospital，College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04532203
263	An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection	Recruiting	No Results Available	Diffuse Large B Cell Lymphoma	Biological: Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells	First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04486872
264	A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL	Recruiting	No Results Available	Acute Lymphoblastic Leukemia|Non-hodgkin Lymphoma,B Cell	Drug: Humanized CD19 CAR-T cells	The First Affiliated Hospital，College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04532268
265	CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma	Recruiting	No Results Available	Lymphoma, Non-Hodgkin|Relapsed Non Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Non Hodgkin Lymphoma|Lymphoma|B Cell Lymphoma|B Cell Non-Hodgkin's Lymphoma	Genetic: CB-010|Drug: Cyclophosphamide|Drug: Fludarabine	Chao Family Comprehensive Cancer Center/University of California Irvine, Orange, California, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT04637763
266	CD19-specific CAR-T Cells in CLL/SLL and DLBCL	Recruiting	No Results Available	Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Diffuse Large B-cell Lymphoma; Acute Lymphoblastic Leukemia	Drug: YTB323 and ibrutinib|Drug: YTB323 single agent	University of Chicago Medical Center Hematology and Oncology, Chicago, Illinois, United States|University of Kansas Cancer Center SC - CTL019C2201, Westwood, Kansas, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Sarah Cannon Research Institute Drug Ship - 4, Nashville, Tennessee, United States|Medical College of Wisconsin, Inc., Milwaukee, Wisconsin, United States|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Paris Cedex 10, France|Novartis Investigative Site, Pierre Benite Cedex, France|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Spain	https://ClinicalTrials.gov/show/NCT03960840
267	Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma	Recruiting	No Results Available	Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive	Biological: Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells	Fujian Medical University Union Hospital, Fuzhou, Fujian, China	https://ClinicalTrials.gov/show/NCT04215016
268	CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL	Not yet recruiting	No Results Available	B-cell Lymphoma Refractory|B-cell Lymphoma Recurrent	Biological: CD19 and CD22 targeted CAR-T cells	Department of Hematology, Xinqiao Hospital, ChongQing, Chongqing, China	https://ClinicalTrials.gov/show/NCT04303247
269	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	Recruiting	No Results Available	Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma|Recurrent Transformed B-Cell Non-Hodgkin Lymphoma|Recurrent Transformed Chronic Lymphocytic Leukemia|Refractory Marginal Zone Lymphoma|Refractory Transformed B-Cell Non-Hodgkin Lymphoma|Refractory Transformed Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma	Biological: Chimeric Antigen Receptor T-Cell Therapy|Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis|Drug: Fludarabine Phosphate	Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT03277729
270	Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL	Not yet recruiting	No Results Available	Lymphoma, Non-Hodgkin	Biological: anti-CD19 FasT CAR-T cells	Department of Hematology, Xinqiao Hospital, ChongQing, Chongqing, China	https://ClinicalTrials.gov/show/NCT04638270
271	TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia	Recruiting	No Results Available	Non Hodgkin Lymphoma|Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma	Drug: TC-110 T Cells|Drug: Fludarabine|Drug: Cyclophosphamide	Colorado Blood Cancer Institute, Denver, Colorado, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT04323657
272	Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma	Recruiting	No Results Available	B-ALL|DLBCL|B ALL|Dlbcl-Ci|DLBCL Unclassifiable|DLBCL, Nos Genetic Subtypes|DLBCL Activated B-Cell Type|DLBCL Germinal Center B-Cell Type|Diffuse Large B-cell Lymphoma|HGBL|HGBL, Nos	Drug: 131-I Apamistamab|Biological: CAR T-cell	Memorial Sloan Kettering Cancer Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT04512716
273	Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL	Recruiting	No Results Available	Acute Lymphoblastic Leukemia|Non Hodgkin Lymphoma	Biological: Car-T Cell Therapy	Acıbadem Labcell Cellular Therapy Laboratories, Istanbul, Turkey	https://ClinicalTrials.gov/show/NCT04206943
274	A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL	Not yet recruiting	No Results Available	B-cell Non Hodgkin Lymphoma	Biological: GC022F	Hebei Yanda Ludaopei Hospital, Sanhe, Hebei, China	https://ClinicalTrials.gov/show/NCT04412174
275	Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	Recruiting	No Results Available	CD19 Positive|CD20 Positive|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Small Lymphocytic Lymphoma	Biological: Chimeric Antigen Receptor T-Cell Therapy|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Biological: Tocilizumab	UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States	https://ClinicalTrials.gov/show/NCT04007029
276	CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.	Recruiting	No Results Available	Leukemia Lymphocytic Acute (ALL) in Relapse|Leukemia Lymphocytic Acute (All) Refractory|Lymphoma, B-Cell|CD19 Positive	Genetic: XYF19 CAR-T cell|Drug: Cyclophosphamide|Drug: Fludarabine	Xijing Hospital, Xi'an, Shannxi, China	https://ClinicalTrials.gov/show/NCT04037566
277	EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma	Not yet recruiting	No Results Available	EBV-Related Hodgkin Lymphoma|Lymphoproliferative Disorders|Chronic EBV (Epstein-Barr Virus) Infection Syndrome|EBV Related Non-Hodgkin's Lymphoma	Biological: Dose Level 1A: 2 x 10^7 cells/m2|Biological: Dose Level 2A: 6 x 10^7 cells/m2|Biological: Dose Level 3A: 2 x 10^8 cells/m2|Biological: Dose Level 2B|Biological: Dose Level 3B	Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT04664179
278	A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL	Not yet recruiting	No Results Available	T-cell Acute Lymphoblastic Leukemia|T-lymphoblastic Lymphoma	Biological: Target CD7 CAR-T cells	920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan, China	https://ClinicalTrials.gov/show/NCT04860817
279	A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma	Recruiting	No Results Available	Relapsed Non Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma	Biological: CD19/22 CART|Drug: Tislelizumab	The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China	https://ClinicalTrials.gov/show/NCT04539444
280	Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies	Recruiting	No Results Available	T-cell Acute Lymphoblastic Leukemia|T-cell Acute Lymphoblastic Lymphoma|Acute Myeloid Leukemia|NK Cell Lymphoma	Biological: CD7-specific CAR gene-engineered T cells	Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China	https://ClinicalTrials.gov/show/NCT04033302
281	huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia	Recruiting	No Results Available	Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Adult Acute Lymphoblastic Leukemia|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory B Acute Lymphoblastic Leukemia|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements	Biological: Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis|Other: Pharmacological Study	Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT03103971
282	Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE	Recruiting	No Results Available	Hodgkin's Disease|Non-Hodgkin's Lymphoma|Lymphoproliferative Disease|Lymphoma	Biological: EBV-specific T cells: A|Biological: EBV-specific T cells: B	Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01555892
283	Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.	Recruiting	No Results Available	Mantle Cell Lymphoma|Follicular Lymphoma|Splenic Marginal Zone Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Indolent Non-hodgkin Lymphoma	Drug: CAR.k.28|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Bendamustine	Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States	https://ClinicalTrials.gov/show/NCT04223765
284	CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies	Recruiting	No Results Available	Non Hodgkin Lymphoma (NHL)|Mantle Cell Lymphoma (MCL)	Biological: 8/12-Day Production of Car-T Cells|Biological: 12-Day Production of Car-T Cells	Medical College of Wisconsin and Froedtert Hospital, Milwaukee, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT04186520
285	Administration of T Lymphocytes for Prevention of Relapse of Lymphomas	Recruiting	No Results Available	Hodgkin Disease|Lymphoma|Lymphoma, Non-Hodgkin|Immune System Diseases|Immunoproliferative Disorders|Lymphatic Diseases|Lymphoproliferative Disorders|Neoplasms|Neoplasms by Histologic Type	Drug: ATLCAR.CD30 cells	Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States	https://ClinicalTrials.gov/show/NCT02663297
286	A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies	Recruiting	No Results Available	Leukemia|Lymphoma|Lymphoma, B-Cell	Biological: CAR T-Cell Infusion	Memorial Sloan Kettering Cancer Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT04556266
287	Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies	Recruiting	No Results Available	B-ALL|B-cell Non Hodgkin Lymphoma|DLBCL	Drug: Fludarabine|Drug: Cyclophosphamide|Drug: CD22 CAR	Stanford Medical Center, Stanford, California, United States	https://ClinicalTrials.gov/show/NCT04088890
288	T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies	Recruiting	No Results Available	Acute Lymphoblastic Leukemia, B-precursor|Non-Hodgkin Lymphoma, B-cell	Biological: CD19 CAR T cells	Chaim Sheba Medical Center, Ramat Gan, Israel	https://ClinicalTrials.gov/show/NCT02772198
289	Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL	Recruiting	No Results Available	Lymphoma|Myeloma|Leukemia	Biological: Kappa CD28 T cells	Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00881920
290	A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy	Recruiting	No Results Available	B Cell ALL|B-Cell Lymphoma|B-cell Non Hodgkin Lymphoma	Drug: Anakinra	Memorial Sloan Kettering Cancer Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT04148430
291	CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies	Recruiting	No Results Available	B-Cell Acute Lymphoblastic Leukemia, Adult|B-cell Lymphoma Refractory|B-cell Lymphoma Recurrent	Drug: Fludarabine|Drug: Cyclophosphamide|Biological: CD19-CD34 CAR transduced T cells	Loyola University, Maywood, Illinois, United States	https://ClinicalTrials.gov/show/NCT04214886
292	Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)	Recruiting	No Results Available	Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Acute Lymphocytic Leukemia	Biological: CD19 CAR T Cells|Drug: Fludarabine|Drug: Cyclophosphamide	Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01853631
293	ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)	Recruiting	No Results Available	Lymphomas Non-Hodgkin's B-Cell|Diffuse Large B-cell Lymphoma (DLBCL)|Primary Mediastinal B-cell Lymphoma (PMBCL)|Transformed Follicular Lymphoma (TFL)|Follicular Lymphoma (FL)|Mantle Cell Lymphoma (MCL)	Biological: WZTL002-1 (1928T2z CAR-T cells)|Drug: Cyclophosphamide and Fludarabine lymphodepleting chemotherapy	Wellington Hospital, Capital & Coast District Health Board, Wellington, New Zealand	https://ClinicalTrials.gov/show/NCT04049513
294	A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	Recruiting	No Results Available	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Drug: Daratumumab|Drug: Vincristine|Drug: Prednisone|Drug: Doxorubicin|Biological: Peg-asparaginase|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: 6-mercaptopurine|Drug: Methotrexate	University of Alabama at Birmingham, Birmingham, Alabama, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|Children's Hospital Orange County, Orange, California, United States|Stanford University, Palo Alto, California, United States|University of California San Francisco, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Children'S Healthcare Of Atlanta/Emory Univ. Dept. Of Pediatrics, Atlanta, Georgia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|Washington Univeristy School of Medicine/ Pediatrics, Saint Louis, Missouri, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|New York University Langone Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Dell Children's Medical Center of Central Texas/Children's Blood and Cancer Center, Austin, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Utah Primary Children's Medical Center, Salt Lake City, Utah, United States|Medical College Of Wisconsin, Milwaukee, Wisconsin, United States|Universitair Ziekenhuis Gent - UZ GENT, Gent, Belgium|CHU de Bordeaux, Hopital des Enfants, Bordeaux, France|IHOPE - Hospices civils de Lyon, Lyon, France|Hôpital trousseau- APHP, Paris, France|Hôpital Robert Debré, Paris, France|Hôpital D'Enfants, Vandoeuvre les Nancy, France|Charite-Universitätsmedizin Berlin - Berlin, Berlin, Germany|Universitatsklinikum Essen, Essen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Münster, Münster, Germany|Schneider Children's Medical Center, Petach Tiquva, Israel|Istituto Giannina Gaslini, Genova, Italy|Fondazione MBBM, ASST Monza, Monza, Italy|Ospedale Pediatrico Bambin Gesù, Roma, Italy|AOU Città della Salute e della Scienza di Torino, Presidio Ospedale Infantile Regina Margherita, Torino, Italy|Princess Maxima Center, Utrecht, Netherlands|Hosp. Univ. Vall D'Hebron, Barcelona, Spain|Hosp. Sant Joan de Deu, Esplugues de Llobregat, Spain|Hosp. Infantil Univ. Niño Jesus, Madrid, Spain|Hosp. Univ. La Paz, Madrid, Spain|Hosp. Univ. I Politecni La Fe, Valencia, Spain|Karolinska University Hospital, Stockholm, Sweden|Bristol Royal Hospital for Children, Bristol, United Kingdom|Royal Hospital for Sick Children, Glasgow, United Kingdom|Leeds Children's Hospital, Leeds, United Kingdom|University College London Hospitals, London, United Kingdom|Great Ormond Street Hospital, London, United Kingdom|Royal Manchester Children's Hospital, Manchester, United Kingdom|Royal Marsden Hospital, Surrey, United Kingdom	https://ClinicalTrials.gov/show/NCT03384654
295	Radiation Post-CAR T in Refractory Lymphoma	Not yet recruiting	No Results Available	Hematologic Malignancy|Refractory Lymphoma	Radiation: Radiotherapy	Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT04473937
296	Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma	Not yet recruiting	No Results Available	Relapsed and Refractory|Lymphoid Hematological Malignancies	Drug: GC022F CAR-T cells	The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04626908
297	Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies	Recruiting	No Results Available	Non Hodgkin Lymphoma|Acute Lymphoblastic Leukemia|Chronic Lymphocytic Leukemia	Biological: Fully human anti CD19 CAR-T Cell Dose|Drug: Fludarabine|Drug: Cyclophosphamide	University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States	https://ClinicalTrials.gov/show/NCT04732845
298	A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma	Recruiting	No Results Available	Leukemia|Lymphoma	Biological: SCRI-CAR22v2	Seattle Children's Hospital, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT04571138
299	Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies	Recruiting	No Results Available	Acute Lymphoblastic Leukemia|B Cell Lymphoma	Genetic: Second generation humanized CAR-T cells	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT04008251
300	CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies	Recruiting	No Results Available	Acute Lymphoblastic Leukemia|B Cell Lymphoma	Genetic: Second generation CAR-T cells	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT02965092
301	Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	Recruiting	No Results Available	T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma	Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone|Drug: Doxorubicin Hydrochloride|Drug: Mercaptopurine|Drug: Methotrexate|Drug: Nelarabine|Drug: Pegaspargase|Drug: Prednisone|Drug: Venetoclax|Drug: Vincristine Sulfate	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00501826
302	Axi-cel in CNS Lymphoma	Recruiting	No Results Available	Lymphoma|Lymphoma Cns	Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Axicabtagene Ciloleucel	Dana Farber Cancer Institute, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT04608487
303	Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies	Not yet recruiting	No Results Available	B-cell Acute Lymphoblastic Leukemia|B-cell Lymphoma	Biological: anti-CD19 UCAR-T cells|Drug: Fludarabine|Drug: Cytoxan|Drug: Melphalan	Department of Hematology, Xinqiao Hospital, ChongQing, Chongqing, China	https://ClinicalTrials.gov/show/NCT04264039
304	Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies	Recruiting	No Results Available	Refractory|Relapsed|B Cell Lymphoma|B Cell Leukemia	Biological: CAR-T cells	Henan Cancer Hospital, Zhengzhou, Henan, China|Henan Cancer Hospital, Zhengzhou, Henan, China	https://ClinicalTrials.gov/show/NCT03881774
305	Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma	Recruiting	No Results Available	Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma|Progressive Disease|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory High Grade B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	Biological: Anakinra|Biological: Axicabtagene Ciloleucel|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Fludarabine Phosphate	UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States	https://ClinicalTrials.gov/show/NCT04205838
306	A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy	Recruiting	No Results Available	Acute Lymphoblastic Leukemia|Non-hodgkin Lymphoma	Drug: CTA101	The First Hospital of Zhejiang Medical Colleage Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04227015
307	CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies	Recruiting	No Results Available	Multiple Myeloma in Relapse|Multiple Myeloma, Refractory|Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphocytic Leukaemia Refractory|Non-Hodgkin's Lymphoma, Relapsed|Non-Hodgkin's Lymphoma Refractory	Drug: CD19/BCMA Targeted CAR T-cells and dasatinib|Drug: CD19/BCMA Targeted CAR T-cells	The First Hospital of Zhejiang Medical Colleage Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04603872
308	CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma	Recruiting	No Results Available	Leukemia, B-cell|Lymphoma, B-Cell	Biological: CD19 and CD22 targeted CAR-T cells	920th Hospital of Joint Logistics Support Force, Kunming, Yunnan, China	https://ClinicalTrials.gov/show/NCT04649983
309	In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies	Recruiting	No Results Available	Acute Lymphocytic Leukemia|Lymphoma	Biological: Biological/Genetically Modified T cells|Drug: Cyclophosphamide-based chemotherapy	Memorial Sloan Kettering Cancer Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT01430390
310	Tisagenlecleucel In Primary CNS Lymphoma	Recruiting	No Results Available	Primary CNS Lymphoma|Refractory Primary CNS Lymphoma|Relapsed Primary CNS Lymphoma	Biological: Tisagenlecleucel	Massachusetts General Hospital, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT04134117
311	Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma	Recruiting	No Results Available	Large B-cell Lymphoma	Biological: BZ019	Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, China|Tianjin medical university cancer institute and hospital, Tianjin, China	https://ClinicalTrials.gov/show/NCT04250324
312	CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma	Recruiting	No Results Available	Non Hodgkin Lymphoma	Biological: CD19 CAR-T cells infusion	First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China	https://ClinicalTrials.gov/show/NCT04237428
313	Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma	Recruiting	No Results Available	Refractory B-Cell Non-Hodgkin Lymphoma|Relapsed B-cell Non-Hodgkin Lymphoma	Biological: CAR-CD19 T Cells	Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China|First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT03994913
314	CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.	Not yet recruiting	No Results Available	B-cell Non-Hodgkin's Lymphoma	Biological: CD19/CD20 Dual-CAR-T cells	Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04697290
315	RPTR-147 in Patients With Selected Solid Tumors and Lymphomas	Recruiting	No Results Available	Solid Tumor|Lymphoma	Biological: Arm A: RPTR-147:1|Biological: Arm B: Pembrolizumab|Biological: Arm C: RPTR-147:2	City of Hope, Duarte, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|NYU Langone Health, New York, New York, United States|Carolina BioOncology Institute, Huntersville, North Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT03815682
316	CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma	Not yet recruiting	No Results Available	Relapsed and/or Refractory Acute Lymphoblastic Leukemia|Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma	Drug: CD79b CAR-T Cells	The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04609241
317	Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies	Recruiting	No Results Available	Leukemia|Lymphoma	Biological: Anti-CD22-CAR-transduced T cells	Fengtai District, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03262298
318	Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma	Not yet recruiting	No Results Available	CD19 Positive|CD22 Positive|Minimal Residual Disease|Progressive Disease|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Non-Hodgkin Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Non-Hodgkin Lymphoma	Biological: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells|Drug: Cyclophosphamide|Drug: Fludarabine	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT04029038
319	Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma	Recruiting	No Results Available	Leukemia, B-cell|Lymphoma, B-Cell	Biological: CD19 and CD22 targeted CAR-T cells	Chongqing University Cancer Hospital, Chongqing, Chongqing, China	https://ClinicalTrials.gov/show/NCT04648475
320	Treatment of Hematological Malignancy With Novel CAR-T Cells.	Recruiting	No Results Available	B-cell Non Hodgkin Lymphoma|B-cell Acute Lymphoblastic Leukemia|Multiple Myeloma	Biological: Novel CAR-T	Hunan Provincial People's Hospital, Changsha, Hunan, China	https://ClinicalTrials.gov/show/NCT04191941
321	Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)	Recruiting	No Results Available	Non-Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Mantle-cell Lymphoma|Primary Mediastinal B-cell Lymphoma	Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule|Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule	University of Alabama-Birmingham, Birmingham, Alabama, United States|City of Hope, Duarte, California, United States|University of California San Francisco, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Blood Marrow Transfer Group of Georgia - Northside Hospital, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Fred Hutchinson/University of Washington Cancer Consortium, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT02631044
322	A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia	Recruiting	No Results Available	B Cell Leukemia|B Cell Lymphoma	Biological: ICAR19 CAR-T cells	Weifang People's Hospital, Weifang, Shandong, China	https://ClinicalTrials.gov/show/NCT03383952
323	CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies	Recruiting	No Results Available	B-cell Malignancy|B-cell Lymphoma|B-Cell Acute Lymphoblastic Leukaemia	Biological: CD19 CAR T	Shanghai Tong Ren hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT03559439
324	A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies	Recruiting	No Results Available	Acute Lymphoblastic Leukemia|Non-Hodgkin Lymphoma of Soft Tissue	Drug: Murine CD19 CAR-T cells	The First Affiliated Hospital，College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04532281
325	A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma	Recruiting	No Results Available	B Cell Leukemia|B Cell Lymphoma	Biological: UCART019	Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03166878
326	'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL	Recruiting	No Results Available	Non-Hodgkin Lymphoma	Radiation: Focal radiation therapy (RT)	UT Southwestern Medical Center, Dallas, Texas, United States	https://ClinicalTrials.gov/show/NCT04601831
327	Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation	Recruiting	No Results Available	Leukemia, B-cell|Lymphoma, Hodgkins|Lymphoma, Non-hodgkins|Lymphoma, B-Cell	Procedure: Allogeneic stem cell transplant|Biological: Anti-CDl9-chimeric- antigen-receptor- transduced T cells|Procedure: Leukapheresis	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|National Marrow Donor Program, Minneapolis, Minnesota, United States	https://ClinicalTrials.gov/show/NCT01087294
328	CAR-T Followed by Bispecific Antibodies	Not yet recruiting	No Results Available	Large B-cell Lymphoma	Drug: mosunetuzumab|Drug: glofitamab|Drug: obinutuzumab	Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT04889716
329	CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML	Recruiting	No Results Available	Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma	Biological: CD19-CAR_Lenti T cell	IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy	https://ClinicalTrials.gov/show/NCT04787263
330	Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)	Recruiting	No Results Available	Non-Hodgkin's Lymphoma|B-Cell ALL|B-Cell CLL	Genetic: CD19.CAR-CD28Z T Cells - dose escalation 2|Genetic: CD19.CAR-CD28Z T Cells - dose escalation 1	Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT02050347
331	JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	Recruiting	No Results Available	Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma	Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014|Drug: Cyclophosphamide|Biological: Durvalumab|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study	Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT02706405
332	CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies	Recruiting	No Results Available	B Cell Lymphoma|Acute Lymphoblastic Leukemia, Pediatric|Lymphoma	Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Autologous CD22 CAR T	Stanford Medical Center, Stanford, California, United States	https://ClinicalTrials.gov/show/NCT04088864
333	Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients	Recruiting	No Results Available	NHL	Drug: IM19 CAR-T Cells	Beijing Cancer Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04440436
334	Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)	Recruiting	No Results Available	Hodgkin Disease|Non-Hodgkin Lymphoma|Severe Chronic Active Epstein Barr Virus|T/NK-lymphoproliferative Disease|Nasopharyngeal Carcinoma|Smooth Muscle Tumor	Biological: MABEL CTLs|Drug: Cyclophosphamide|Drug: Fludarabine	Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT02287311
335	Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL	Recruiting	No Results Available	Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Hodgkin Disease	Biological: Antigen-Escalation Stage|Biological: Dose-Escalation Stage|Biological: azacytidine and multiTAA T cells Stage|Biological: Pediatric multiTAA T cells Stage	Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01333046
336	Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies	Recruiting	No Results Available	Follicular Lymphoma|ALL|NHL|Large Cell Lymphoma	Biological: CD22-CAR	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT02315612
337	A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma	Recruiting	No Results Available	Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood|Refractory B-cell Acute Lymphoblastic Leukemia, Childhood|Relapsed/Refractory B-cell Lymphoma, Childhood	Biological: CAR-T19/CAR-T22	Xiangya Hospital Central South University, Changsha, Hunan, China	https://ClinicalTrials.gov/show/NCT04204161
338	A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia	Recruiting	No Results Available	Leukemia|Lymphoma	Biological: Patient-derived CD19- and CD22 specific CAR	Children's Hospital Los Angeles, Los Angeles, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Seattle Children's Hospital, Seattle, Washington, United States|Children's and Women's Health Centre of British Columbia, Vancouver, British Columbia, Canada	https://ClinicalTrials.gov/show/NCT03330691
339	Aflac LL1602 ENCERT	Recruiting	No Results Available	Lymphoblastic Leukemia|Lymphoblastic Lymphoma	Drug: Everolimus|Drug: Nelarabine|Drug: Cyclophosphamide|Drug: Etoposide	Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|Texas Children's Hospital, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT03328104
340	CD22 Redirected Autologous T Cells for ALL	Recruiting	No Results Available	B Cell Leukemias|B Cell Lymphomas	Biological: CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB	Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT02650414
